# EDGAR Filing Document

**Accession Number:** 0000933974
**File Stem:** 0001437749-25-025123
**Filing Date:** 2025-8
**Character Count:** 183899
**Document Hash:** 79a8ba104ba65bd65b708ada6fa90db8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-25-025123.hdr.sgml**: 20250806

**ACCESSION NUMBER**: 0001437749-25-025123

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 99

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250806

**DATE AS OF CHANGE**: 20250806

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Azenta, Inc.
- **CENTRAL INDEX KEY:** 0000933974
- **STANDARD INDUSTRIAL CLASSIFICATION:** SPECIAL INDUSTRY MACHINERY, NEC [3559]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 043040660
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-25434
- **FILM NUMBER:** 251190709

**BUSINESS ADDRESS:**
- **STREET 1:** 200 SUMMIT DRIVE
- **STREET 2:** 6TH FLOOR
- **CITY:** BURLINGTON
- **STATE:** MA
- **ZIP:** 01803
- **BUSINESS PHONE:** (978) 262-2400

**MAIL ADDRESS:**
- **STREET 1:** 200 SUMMIT DRIVE
- **STREET 2:** 6TH FLOOR
- **CITY:** BURLINGTON
- **STATE:** MA
- **ZIP:** 01803

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Brooks Automation, Inc.
- **DATE OF NAME CHANGE:** 20190521

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BROOKS AUTOMATION INC
- **DATE OF NAME CHANGE:** 20030228

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BROOKS-PRI AUTOMATION INC
- **DATE OF NAME CHANGE:** 20020514

?xml version='1.0' encoding='ASCII'? azta20250630_10q.htm

[**Table of Contents**](#toc)

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM 10-Q**

------

**(Mark One)**

---

| | |
|:---|:---|
| ☒ | **Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** |
| **For the quarterly period ended: June 30, 2025** | **For the quarterly period ended: June 30, 2025** |
| **OR** | **OR** |
| ☐ | **Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** |

---

**For the transition period from __________ to _________**

**Commission File Number 000-25434**

------

**AZENTA, INC.**

(Exact name of registrant as specified in its charter)

------

---

| | |
|:---|:---|
| **Delaware** | **04-3040660** |
| (State or other jurisdiction of | (I.R.S. Employer |
| incorporation or organization) | Identification No.) |

---

**200 Summit Drive, 6<sup>th</sup> Floor** 

**Burlington, Massachusetts**

(Address of principal executive offices)

------

**01803**

(Zip Code)

------

Registrant's telephone number, including area code: **(888) 229-3682**

------

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| <u>**Title of each class**</u> | <u>**Trading Symbol(s)**</u> | <u>**Name of each exchange on which registered**</u> |
| Common Stock, $0.01 par value | AZTA | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐

------

[**Table of Contents**](#toc)

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act:

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐&nbsp;&nbsp;&nbsp;&nbsp;No ☒

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date, August 1, 2025: common stock, $0.01 par value, and 45,839,728 shares outstanding.

------

[**Table of Contents**](#toc)

**AZENTA, INC.**

**Table of Contents**

---

| | |
|:---|:---|
|  | **PAGE NUMBER** |
| [<u>**PART I. FINANCIAL INFORMATION**</u>](#partone) | [<u>**PART I. FINANCIAL INFORMATION**</u>](#partone) |
| [<u>Item 1. Financial Statements</u>](#finstmts) | [4](#finstmts) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [<u>Condensed Consolidated Balance Sheets as of June 30, 2025 and September 30, 2024</u>](#bs) (unaudited) | [4](#bs) |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [<u>Condensed Consolidated Statements of Operations for the three and nine months ended June 30, 2025 and 2024</u>](#ops) (unaudited) | [5](#ops) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [<u>Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended June 30, 2025 and 2024</u>](#compinc) (unaudited) | [6](#compinc) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [<u>Condensed Consolidated Statements of Cash Flows for the nine months ended June 30, 2025 and 2024</u>](#cf) (unaudited) | [7](#cf) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [<u>Condensed Consolidated Statements of Changes in Stockholders</u><u>'</u> <u>Equity for the three and nine months ended June 30, 2025 and 2024</u>](#se) (unaudited) | [9](#se) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [<u>Notes to Condensed Consolidated Financial Statements</u>](#notes) (unaudited) | [11](#notes) |
| [<u>Item 2. Management</u><u>'</u><u>s Discussion and Analysis of Financial Condition and Results of Operations</u>](#mda) | [35](#mda) |
| [<u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u>](#quant) | [45](#quant) |
| [<u>Item 4. Controls and Procedures</u>](#controls) | [45](#controls) |
| [<u>**PART II. OTHER INFORMATION**</u>](#parttwo) | [<u>**PART II. OTHER INFORMATION**</u>](#parttwo) |
| [<u>Item 1. Legal Proceedings</u>](#legal) | [47](#legal) |
| [<u>Item 1A. Risk Factors</u>](#risk) | [47](#risk) |
| [<u>Item 5. Other Information</u>](#otherinfo) | [47](#otherinfo) |
| [<u>Item 6. Exhibits</u>](#exhibits) | [48](#exhibits) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [<u>Signatures</u>](#sigs) | [49](#sigs) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2

------

[**Table of Contents**](#toc)

**INFORMATION RELATED TO FORWARD-LOOKING STATEMENTS**

This Quarterly Report on Form 10-Q contains statements that are, or may be considered to be, forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended, Section-27A of the Securities Act of 1933, as amended, or the "Securities Act", and Section 21E of the Securities Exchange Act of 1934, as amended, or the "Exchange Act". All statements that are not historical facts, including statements about our beliefs or expectations, are forward-looking statements. These statements may be identified by such forward-looking, terminology as "expect," "estimate," "intend," "believe," "anticipate," "may," "will," "should," "could," "continue," "likely" or similar statements or variations of such terms. Forward-looking statements include, but are not limited to, statements that relate to our future revenue, margins, costs, operating expenses, tax expenses, capital expenditures, earnings, profitability, product development, demand, acceptance and market share, competitiveness, market opportunities and performance, levels of research and development, the success of our marketing, sales and service efforts, outsourced activities, anticipated manufacturing, customer and technical requirements, the ongoing viability of the solutions that we offer and our customers' success, our management's plans and objectives for our current and future operations and business focus, litigation, our ability to retain, hire and integrate skilled personnel, our ability to identify and address increased cybersecurity risks, including as a result of employees continuing to work remotely, the anticipated growth prospects of our business, the expected benefits and other statements relating to our divestitures and acquisitions, including the timing therefor, the adequacy, effectiveness and success of cost saving plans and our business transformation initiatives, our ability to continue to identify acquisition targets and successfully acquire and integrate desirable products and services and realize expected revenues and revenue synergies, our adoption of newly issued accounting guidance, the levels of customer spending, our dependence on key suppliers or vendors to obtain services for our business on acceptable terms, including the impact of supply chain disruptions, general economic conditions, the impact of inflation and tariffs, and the sufficiency of financial resources to support future operations and the material weaknesses in our internal control over financial reporting. Such statements are based on current expectations and involve risks, uncertainties, and other factors which may cause the actual results, our performance or our achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include the risk factors which are set forth in Part I, Item 1A "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2024, or the "2024 Annual Report on Form 10-K", filed with the Securities and Exchange Commission, or "SEC", on November 27, 2024, as updated and/or supplemented in subsequent filings with the SEC, including as set forth in Part II, Item 1A "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed with the SEC on May 9, 2025. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report on Form 10-Q and are based on information reasonably known to us at such time. We do not undertake any obligation to release revisions to these forward-looking statements, to reflect events or circumstances that occur after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence or effect of anticipated or unanticipated events. Precautionary statements made herein should be read as being applicable to all related forward-looking statements wherever they appear in this Quarterly Report on Form 10-Q. Any additional precautionary statements made in our 2024 Annual Report on Form 10-K should be read as being applicable to all related forward-looking statements whenever they appear in this Quarterly Report on Form 10-Q.

Unless the context indicates otherwise, references in this Quarterly Report on Form 10-Q to "we", "us", "our", "the Company", and other similar references refer to Azenta, Inc. and its consolidated subsidiaries.

**TRADEMARKS, TRADE NAMES AND SERVICE MARKS**

This Quarterly Report on Form 10-Q includes our trademarks, trade names and service marks, which are our property and are protected under applicable intellectual property laws. Solely for convenience, trademarks, trade names and service marks may appear in this Quarterly Report on Form 10-Q without the <sup>®</sup>, <sup>TM</sup> and <sup>SM</sup> symbols, but such references are not intended to indicate, in any way, that we or the applicable owner forgo or will not assert, to the fullest extent permitted under applicable law, our rights or the rights of any applicable licensors to these trademarks, trade names and service marks. We do not intend our use or display of other parties' trademarks, trade names or service marks to imply, and such use or display should not be construed to imply a relationship with, or endorsement or sponsorship of us by, these other parties.

**INDUSTRY AND OTHER DATA**

Unless otherwise indicated, information contained in this Quarterly Report on Form 10-Q concerning our industry and the markets in which we operate, including our general expectations, market position and market opportunity, is based on management's estimates and research, as well as industry and general publications and research, surveys and studies conducted by third parties. We believe the information from these third-party publications, research, surveys and studies included in this Quarterly Report on Form 10-Q is reliable. Management's estimates are derived from publicly available information, their knowledge of our industry and their assumptions based on such information and knowledge, which we believe to be reasonable. This data involves a number of assumptions and limitations which are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the 2024 Annual Report on Form 10-K and those described in this Quarterly Report on Form 10-Q under "Information Related to Forward-Looking Statements" above and Part II, Item 1A "Risk Factors" below, as updated and/or supplemented in subsequent filings with the SEC. These and other factors could cause our future performance to differ materially from our assumptions and estimates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3

------

[**Table of Contents**](#toc)

**PART I. FINANCIAL INFORMATION**

***Item 1. Financial Statements***

AZENTA, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

(In thousands, except share and per share data)

---

| | | |
|:---|:---|:---|
|  | **June 30,** | **September 30,** |
|  | **2025** | **2024** |
| Assets |  |  |
| Current assets |  |  |
| Cash and cash equivalents | $270040 | $280030 |
| Short-term marketable securities | 48817 | 151162 |
| Accounts receivable, net of allowance for expected credit losses ($5,526 and $5,349, respectively) | 124535 | 156273 |
| Inventories | 80506 | 78923 |
| Short-term restricted cash | 2312 | 2069 |
| Prepaid expenses and other current assets | 75243 | 75456 |
| Current assets held for sale | 77025 | 88894 |
| Total current assets | 678478 | 832807 |
| Property, plant and equipment, net | 153641 | 155622 |
| Long-term marketable securities | 222168 | 49454 |
| Long-term deferred tax assets | 779 | 837 |
| Operating lease right-of-use assets | 60660 | 60406 |
| Goodwill | 703614 | 691409 |
| Intangible assets, net | 108136 | 125042 |
| Other assets | 6180 | 10670 |
| Noncurrent assets held for sale | 85479 | 173794 |
| Total assets | $2019135 | $2100041 |
| Liabilities and stockholders' equity |  |  |
| Current liabilities |  |  |
| Accounts payable | $37984 | $33344 |
| Deferred revenue | 38216 | 30493 |
| Derivative liability | 34656 | 1915 |
| Accrued warranty and retrofit costs | 5373 | 5213 |
| Accrued compensation and benefits | 31540 | 27785 |
| Accrued customer deposits | 27220 | 22324 |
| Accrued income taxes payable | 8847 | 9266 |
| Accrued expenses and other current liabilities | 29884 | 44449 |
| Current liabilities held for sale | 31715 | 30050 |
| Total current liabilities | 245435 | 204839 |
| Long-term tax reserves | 425 | 398 |
| Long-term deferred tax liabilities | 20583 | 18084 |
| Long-term operating lease liabilities | 52628 | 56683 |
| Other long-term liabilities | 9339 | 8874 |
| Noncurrent liabilities held for sale | 17091 | 42196 |
| Total liabilities | 345501 | 331074 |
| Stockholders' equity |  |  |
| Preferred stock, $0.01 par value - 1,000,000 shares authorized, no shares issued or outstanding |  |  |
| Common stock, $0.01 par value - 125,000,000 shares authorized, 59,246,710 shares issued and 45,784,841 shares outstanding at June 30, 2025; 59,031,953 shares issued and 45,570,084 shares outstanding at September 30, 2024 | 593 | 590 |
| Additional paid-in capital | 523395 | 505958 |
| Accumulated other comprehensive loss | (19635) | (13464) |
| Treasury stock, at cost - 13,461,869 shares at June 30, 2025 and September 30, 2024 | (200956) | (200956) |
| Retained earnings | 1370237 | 1476839 |
| Total stockholders' equity | 1673634 | 1768967 |
| Total liabilities and stockholders' equity | $2019135 | $2100041 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4

------

[**Table of Contents**](#toc)

AZENTA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(In thousands, except per share data)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended**  | **Three Months Ended**  | **Nine Months Ended** | **Nine Months Ended** |
|  | **June 30,** | **June 30,** | **June 30,** | **June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Revenue |  |  |  |  |
| Products | $39387 | $44028 | $125169 | $126507 |
| Services | 104555 | 100264 | 309701 | 295865 |
| Total revenue | 143942 | 144292 | 434870 | 422372 |
| Cost of revenue |  |  |  |  |
| Products | 19592 | 26306 | 68085 | 77104 |
| Services | 56590 | 52508 | 164468 | 157383 |
| Total cost of revenue | 76182 | 78814 | 232553 | 234487 |
| Gross profit | 67760 | 65478 | 202317 | 187885 |
| Operating expenses |  |  |  |  |
| Research and development | 6685 | 6911 | 19934 | 21957 |
| Selling, general and administrative | 61035 | 63972 | 205836 | 202919 |
| Impairment of intangible assets |  |  |  | 4658 |
| Restructuring charges | 754 | 1701 | 4765 | 5915 |
| Total operating expenses | 68474 | 72584 | 230535 | 235449 |
| Operating loss | (714) | (7106) | (28218) | (47564) |
| Other income |  |  |  |  |
| Interest income, net | 4973 | 7925 | 13760 | 27359 |
| Other income (expense), net | (821) | (377) | 1539 | (127) |
| Income (loss) before income taxes | 3438 | 442 | (12919) | (20332) |
| Income tax expense | 2758 | 600 | 14007 | 3220 |
| Income (loss) from continuing operations | 680 | (158) | (26926) | (23552) |
| Loss from discontinued operations, net of tax | (53486) | (6424) | (79676) | (135634) |
| Net loss | $(52806) | $(6582) | $(106602) | $(159186) |
| Basic net income (loss) per share: |  |  |  |  |
| Income (loss) from continuing operations | $0.01 | $(0.00) | $(0.59) | $(0.43) |
| Loss from discontinued operations, net of tax | $(1.17) | $(0.12) | $(1.74) | $(2.47) |
| Basic net loss per share | $(1.15) | $(0.12) | $(2.33) | $(2.90) |
| Diluted net income (loss) per share: |  |  |  |  |
| Income (loss) from continuing operations | $0.01 | $(0.00) | $(0.59) | $(0.43) |
| Loss from discontinued operations, net of tax | $(1.17) | $(0.12) | $(1.74) | $(2.47) |
| Diluted net loss per share | $(1.15) | $(0.12) | $(2.33) | $(2.90) |
| Weighted average shares used in computing net income (loss) per share: |  |  |  |  |
| Basic | 45780 | 52963 | 45712 | 54914 |
| Diluted | 45823 | 52963 | 45712 | 54914 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5

------

[**Table of Contents**](#toc)

AZENTA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(unaudited)

(In thousands)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended*** | ***Three Months Ended*** | ***Nine Months Ended*** | ***Nine Months Ended*** |
|  | ***June 30,*** | ***June 30,*** | ***June 30,*** | ***June 30,*** |
|  | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| Net loss | $(52806) | $(6582) | $(106602) | $(159186) |
| Other comprehensive income (loss), net of tax |  |  |  |  |
| Net investment hedge currency translation adjustment, net of tax effects of $0 and $0 for the three and nine months ended June 30, 2025, respectively, and $(109) and $2,728 for the three and nine months ended June 30, 2024, respectively | (34656) | 317 | (39744) | (7971) |
| Foreign currency translation adjustments | 57321 | (4000) | 33462 | 21725 |
| Changes in unrealized losses on marketable securities, net of tax effects of $0 and $0 for the three and nine months ended June 30, 2025, respectively, and $(179) and $(1300) for the three and nine months ended June 30, 2024, respectively | (101) | 523 | 262 | 3799 |
| Actuarial loss on pension plans, net of tax effects of $17 and $52 for the three and nine months ended June 30, 2025, respectively, and $3 and $7 for the three and nine months ended June 30, 2024, respectively | (50) | (7) | (151) | (22) |
| Total other comprehensive income (loss), net of tax | 22514 | (3167) | (6171) | 17531 |
| Comprehensive loss | $(30292) | $(9749) | $(112773) | $(141655) |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6

------

[**Table of Contents**](#toc)

AZENTA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(In thousands)

---

| | | |
|:---|:---|:---|
|  | ***Nine Months Ended June 30,*** | ***Nine Months Ended June 30,*** |
|  | ***2025*** | ***2024*** |
| Cash flows from operating activities |  |  |
| Net loss | $(106602) | $(159186) |
| Adjustments to reconcile net loss to net cash provided by operating activities: |  |  |
| Depreciation and amortization | 46775 | 66899 |
| Impairment of goodwill and intangible assets |  | 115975 |
| Loss on assets held for sale | 93025 |  |
| Inventory write-downs and other asset write-offs | 3866 | 10745 |
| Stock-based compensation | 15887 | 12622 |
| Amortization and accretion on marketable securities | (1318) | (4706) |
| Deferred income taxes | (20025) | (12478) |
| Loss on disposals of property, plant and equipment | 759 | 297 |
| Changes in operating assets and liabilities: |  |  |
| Accounts receivable | 38799 | (10923) |
| Inventories | (10069) | 14107 |
| Accounts payable | (702) | 2831 |
| Deferred revenue | 7156 | (1635) |
| Accrued warranty and retrofit costs | 36 | (1080) |
| Accrued compensation and tax withholdings | 3010 | (2825) |
| Accrued restructuring costs | (51) | 1125 |
| Other assets and liabilities | (535) | 383 |
| Net cash provided by operating activities | 70011 | 32151 |
| Cash flows from investing activities |  |  |
| Purchases of property, plant and equipment | (25997) | (28013) |
| Purchases of marketable securities | (312990) | (378275) |
| Sales and maturities of marketable securities | 242527 | 431544 |
| Proceeds from other investment | 2130 |  |
| Net investment hedge settlement | 3043 | 1476 |
| Net cash (used in) provided by investing activities | (91287) | 26732 |
| Cash flows from financing activities |  |  |
| Proceeds from issuance of common stock | 1553 | 1678 |
| Payments of finance leases | (585) | (584) |
| Share repurchases |  | (412755) |
| Excise tax payment for settled share repurchases | (11376) |  |
| Net cash used in financing activities | (10408) | (411661) |
| Effects of exchange rate changes on cash, cash equivalents and restricted cash | 4510 | 15596 |
| Net decrease in cash, cash equivalents and restricted cash | (27174) | (337182) |
| Cash, cash equivalents and restricted cash, beginning of period | 320990 | 684045 |
| Cash, cash equivalents and restricted cash, end of period | $293816 | $346863 |
| Supplemental disclosures: |  |  |
| Cash paid for income taxes, net | 2243 | 6710 |
| Purchases of property, plant and equipment included in accounts payable and accrued expenses | 4652 | 2575 |
| Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets |  |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7

------

[**Table of Contents**](#toc)

---

| | | |
|:---|:---|:---|
|  | **June 30,** | **September 30,** |
|  | **2025** | **2024** |
| Cash and cash equivalents of continuing operations | $270040 | $280030 |
| Cash included in current assets held for sale | 15000 | 30899 |
| Short-term restricted cash | 2312 | 2069 |
| Long-term restricted cash included in other assets | 6464 | 7992 |
| Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows | $293816 | $320990 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8

------

[**Table of Contents**](#toc)

AZENTA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

(unaudited)

(In thousands, except share data)

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  | ***Common*** |  | ***Accumulated*** |  |  |  |
|  | ***Common*** | ***Stock at*** | ***Additional*** | ***Other*** |  |  |  |
|  | ***Stock*** | ***Par*** | ***Paid-In*** | ***Comprehensive*** | ***Retained*** | ***Treasury*** | ***Total*** |
|  | ***Shares*** | ***Value*** | ***Capital*** | ***Income (Loss)*** | ***Earnings*** | ***Stock*** | ***Equity*** |
| **Balance March 31, 2025** | 59237887 | $593 | $520961 | $(42149) | $1423043 | $(200956) | $1701492 |
| Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes | 8823 |  |  |  |  |  |  |
| Stock-based compensation | *—* |  | 2434 |  |  |  | 2434 |
| Net loss | *—* |  |  |  | (52806) |  | (52806) |
| Net investment hedge currency translation adjustment, net of tax | *—* |  |  | (34656) |  |  | (34656) |
| Foreign currency translation adjustments | *—* |  |  | 57321 |  |  | 57321 |
| Changes in unrealized losses on marketable securities, net of tax | *—* |  |  | (101) |  |  | (101) |
| Actuarial loss on pension plans, net of tax | *—* |  |  | (50) |  |  | (50) |
| **Balance June 30, 2025** | 59246710 | $593 | $523395 | $(19635) | $1370237 | $(200956) | $1673634 |
| **Balance March 31, 2024** | 68075910 | $681 | $999333 | $(41728) | $1488405 | $(223820) | $2222871 |
| Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes | 6855 | 0 | 1678 |  |  |  | 1678 |
| Open market repurchases | (4225825) | (42) |  |  |  | (228178) | (228220) |
| Retirement of treasury shares | *—* |  | (246560) |  |  | 246560 |  |
| Stock-based compensation | *—* |  | 3818 |  |  |  | 3818 |
| Net loss | *—* |  |  |  | (6582) |  | (6582) |
| Net investment hedge currency translation adjustment, net of tax | *—* |  |  | 317 |  |  | 317 |
| Foreign currency translation adjustments | *—* |  |  | (4000) |  |  | (4000) |
| Changes in unrealized losses on marketable securities, net of tax |  |  |  | 523 |  |  | 523 |
| Actuarial loss on pension plans, net of tax | *—* |  |  | (7) |  |  | (7) |
| **Balance June 30, 2024** | 63856940 | $639 | $758269 | $(44895) | $1481823 | $(205438) | $1990398 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9

------

[**Table of Contents**](#toc)

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  | ***Common*** |  | ***Accumulated*** |  |  |  |
|  | ***Common*** | ***Stock at*** | ***Additional*** | ***Other*** |  |  |  |
|  | ***Stock*** | ***Par*** | ***Paid-In*** | ***Comprehensive*** | ***Retained*** | ***Treasury*** | ***Total*** |
|  | ***Shares*** | ***Value*** | ***Capital*** | ***Income (Loss)*** | ***Earnings*** | ***Stock*** | ***Equity*** |
| **Balance September 30, 2024** | 59031953 | $590 | $505958 | $(13464) | $1476839 | $(200956) | $1768967 |
| Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes | 214757 | 3 | 1550 |  |  |  | 1553 |
| Stock-based compensation | *—* |  | 15887 |  |  |  | 15887 |
| Net loss | *—* |  |  |  | (106602) |  | (106602) |
| Net investment hedge currency translation adjustment, net of tax | *—* |  |  | (39744) |  |  | (39744) |
| Foreign currency translation adjustments | *—* |  |  | 33462 |  |  | 33462 |
| Changes in unrealized losses on marketable securities, net of tax | *—* |  |  | 262 |  |  | 262 |
| Actuarial loss on pension plans, net of tax | *—* |  |  | (151) |  |  | (151) |
| **Balance June 30, 2025** | 59246710 | $593 | $523395 | $(19635) | $1370237 | $(200956) | $1673634 |
| **Balance September 30, 2023** | 71294247 | $713 | $1156160 | $(62426) | $1641009 | $(200956) | $2534500 |
| Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes | 224802 | 3 | 1675 |  |  |  | 1678 |
| Open market repurchases | (7662109) | (54) |  |  |  | (416693) | (416747) |
| Retirement of treasury shares | *—* | (23) | (412188) |  |  | 412211 |  |
| Stock-based compensation | *—* |  | 12622 |  |  |  | 12622 |
| Net loss | *—* |  |  |  | (159186) |  | (159186) |
| Net investment hedge currency translation adjustment, net of tax | *—* |  |  | (7971) | *.* |  | (7971) |
| Foreign currency translation adjustments | *—* |  |  | 21725 |  |  | 21725 |
| Changes in unrealized losses on marketable securities, net of tax |  |  |  | 3799 |  |  | 3799 |
| Actuarial loss on pension plans, net of tax | *—* |  |  | (22) |  |  | (22) |
| **Balance June 30, 2024** | 63856940 | $639 | $758269 | $(44895) | $1481823 | $(205438) | $1990398 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10

------

[**Table of Contents**](#toc)

AZENTA, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

***1.* Nature of Operations** 

Azenta, Inc. ("Azenta", or the "Company") is a leading global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Company entered the life sciences market in *2011,* leveraging its in-house precision automation and cryogenics capabilities that it was then applying in the semiconductor manufacturing market. This led the Company to develop and provide solutions for automated ultra-cold storage. Since then, the Company has expanded its life sciences offerings through internal investments and a series of acquisitions. The Company supports its customers from research and clinical development to commercialization with its sample management and automated storage, as well as genomic services expertise to help its customers bring impactful and breakthrough therapies to market faster. The Company understands the importance of sample integrity and offers a broad portfolio of products and services supporting customers at every stage of the life cycle of samples, including procurement, automated storage systems, genomic services and a multitude of sample consumables, informatics and data software, and sample repository services. The Company's expertise, global footprint, and leadership positions enable it to be a trusted global partner to pharmaceutical, biotechnology, and life sciences research institutions.

***Discontinued Operations***

During the *first* quarter of fiscal year *2025,* following approval by the Board of Directors of the Company, the Company publicly announced its plan to sell the B Medical Systems business. The B Medical Systems business operates as a separate business unit within the Company and focuses on the manufacturing and distribution of temperature-controlled storage and transportation solutions in international markets to governments, health institutions, and non-government organizations.

The Company determined that the B Medical Systems business met the "held for sale" criteria and "discontinued operations" criteria in accordance with Financial Accounting Standard Boards ("FASB") Accounting Standards Codification ("ASC") *205, Presentation of Financial Statements* ("FASB ASC *205"*) as of *November 12, 2024.* Results related to the B Medical Systems business are included within discontinued operations. Please refer to Note *3, Discontinued Operations* for further information about the discontinued business. The Condensed Consolidated Balance Sheet and Condensed Consolidated Statements of Operations, as well as the notes to the Condensed Consolidated Financial Statements, have been reclassified for all periods presented to reflect the discontinuation of the B Medical Systems business in accordance with FASB ASC *205.* The discussion in these notes to Condensed Consolidated Financial Statements, unless otherwise stated, relate solely to the Company's continuing operations.

Also included in discontinued operations is a loss contingency related to the Company's sale of the semiconductor automation business in *February 2022.* The Company accrued a liability for the loss contingency and had an accrued liability of $2.1 million as of *June 30, 2025*.

***2.* Summary of Significant Accounting Policies** 

***Principles of Consolidation and Basis of Presentation***

The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and all entities where it has a controlling financial interest and have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP"). All intercompany balances and transactions have been eliminated in consolidation.

The accompanying year-end balance sheet as of *September 30, 2024* was derived from audited, consolidated financial statements but does *not* include all disclosures required by GAAP. The unaudited interim Condensed Consolidated Financial Statements have been prepared on the same basis as the audited, consolidated financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company's financial position, results of operations, and cash flows for the periods presented.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *11*

------

[**Table of Contents**](#toc)

Certain information and disclosures normally included in the Company's annual consolidated financial statements have been condensed or omitted and, accordingly, the accompanying financial information should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form *10*-K for the fiscal year ended *September 30, 2024* and filed with the U.S. Securities and Exchange Commission ("SEC") on *November 27, 2024 (*the *"2024* Annual Report on Form *10*-K").

***Revisions to Previously Issued Financial Statements and Financial Information***

As previously disclosed in the *2024* Annual Report on Form *10*-K, in connection with the preparation of its fiscal year *2024* financial statements, the Company identified classification errors in its Condensed Consolidated Statement of Cash Flows for the year ended *September 30, 2023* and the Condensed Consolidated Statements of Cash Flows for the interim periods ended *March 31, 2023, June 30, 2023, December 31, 2023, March 31, 2024,* and *June 30, 2024.* Specifically, the Company's historical classification of the effects of exchange rate changes on the Company's foreign denominated cash and cash equivalent balances was misclassified between the effects of exchange rate changes on cash and cash equivalents and cash flows from operating activities in its Consolidated Statement of Cash Flows for the year ended *September 30, 2023* and its Condensed Consolidated Statements of Cash Flows for the interim periods ended *June 30, 2023, December 31, 2023, March 31, 2024,* and *June 30, 2024.* Additionally, the Company corrected for immaterial classification errors in between cash flows from operating activities, investing activities and financing activities, and supplemental disclosures for all revised periods. The Company's Condensed Consolidated Statements of Cash Flows for the interim periods ended *March 31, 2023, June 30, 2023, December 31, 2023, March 31, 2024,* and *June 30, 2024* have been revised and disclosed in Note *21, Revision of Previously Issued Unaudited Quarterly Information*, in the notes to the audited consolidated financial statements included in the section titled "Financial Statements and Supplementary Data" in Part II, Item *8* of the *2024* Annual Report on Form *10*-K.

The effect on the Condensed Consolidated Statement of Cash Flows for the interim period ended *June 30, 2024* is as follows (in thousands):

---

| | | | |
|:---|:---|:---|:---|
|  | **Nine months ended June 30, 2024** | **Nine months ended June 30, 2024** | **Nine months ended June 30, 2024** |
|  | **As Reported** | **Adjustments** | **As Revised** |
| Cash flows from operating activities |  |  |  |
| Inventories | $11433 | $2674 | $14107 |
| Other assets and liabilities | 7484 | (7101) | 383 |
| Net cash provided by operating activities | $36578 | $(4427) | $32151 |
| Cash flows from investing activities |  |  |  |
| Purchase of property, plant and equipment | $(25339) | $(2674) | $(28013) |
| Net cash used in investing activities | $29406 | $(2674) | $26732 |
| Effects of exchange rate changes on cash and cash equivalents | $8495 | $7101 | $15596 |
| Supplemental disclosures: |  |  |  |
| Purchases of property, plant and equipment included in accounts payable and accrued expenses | $2203 | $372 | $2575 |

---

The Company assessed the effect of the errors on prior periods under the guidance of SEC Staff Accounting Bulletin *No. 99, Materiality*, codified in ASC *250, Accounting Changes and Error Corrections*. Based on its assessment, the Company determined that the error correction is *not* material to any previously issued financial statements. The correction has *no* impact on the Company's previously reported consolidated net income, financial position, net change in cash, cash equivalents, and restricted cash, or total cash, cash equivalents, and restricted cash as previously reported on the Company's Consolidated Statements of Cash Flows.

***Reclassification***

A previously reported amount has been reclassified to conform to the current period presentation. The derivative liability was included in "Accrued expenses and other current liabilities" as of *September 30, 2024* in the Condensed Consolidated Balance Sheets and has been conformed for the current period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *12*

------

[**Table of Contents**](#toc)

***Use of Estimates***

The preparation of financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect amounts reported in the financial statements and notes thereto. Although these estimates are based on the Company's knowledge of current events and actions it *may* undertake in the future, actual results *may* differ from these estimates. Estimates are associated with recording accounts receivable, inventories, goodwill, intangible assets other than goodwill, long-lived assets, derivative financial instruments, deferred income taxes, warranty obligations, revenue over time, stock-based compensation expense, and other accounts. The Company assesses the estimates on an ongoing basis and records changes in estimates in the period they occur and become known.

***Foreign Currency Translation***

Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Foreign currency exchange gains (losses) generated from the settlement and remeasurement of these transactions are recognized in earnings and presented within "Other income" in the Condensed Consolidated Statements of Operations. Net foreign currency transaction and remeasurement loss were $0.2 million and $0.5 million for the *three* months ended *June 30, 2025* and *2024*, respectively. Net foreign currency transaction and remeasurement loss were $1.3 million and $1.5 million during the *nine* months ended *June 30, 2025* and *2024*, respectively.

***Recently Issued Accounting Pronouncements***

In *November 2023,* the FASB issued Accounting Standards Update ("ASU") *2023*-*07, Segment Reporting (Topic *280*): Improvements to Reportable Segment Disclosures*. The ASU requires the disclosure of incremental segment information on an annual and interim basis, primarily through enhanced disclosures pertaining to significant segment expenses. This update is effective for annual periods beginning after *December 15, 2023,* and interim periods within fiscal years beginning after *December 15, 2024,* and requires retrospective application to all prior periods presented in the financial statements. The Company does *not* expect the adoption of this standard to impact its disclosures at the end of fiscal year *2025.*

In *December 2023,* the FASB issued ASU *2023*-*09, Income Taxes (Topic *740*): Improvements to Income Tax Disclosures*. The ASU is intended to enhance the transparency and decision usefulness of income tax disclosures primarily through changes to the rate reconciliation and income taxes paid information. This update is effective for annual periods beginning after *December 15, 2024,* though early adoption is permitted. The Company does *not* expect the adoption of this standard to impact its disclosures until fiscal year *2026.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *13*

------

[**Table of Contents**](#toc)

In *2021,* the Organization of Economic Cooperation and Development introduced its Pillar II Framework Model Rules ("Pillar *2"*), which are designed to impose a *15%* global minimum tax on the earnings of in-scope multinational corporations on a country-by-country basis. Certain aspects of Pillar *2* took effect on *January 1, 2024* while other aspects go into effect on *January 1, 2025.* The Company does *not* expect the adoption of this standard to have a material impact on its consolidated financial statements as the Company does *not* expect to meet the consolidated revenue threshold of *€750* million over the next *twelve* months.

In *November 2024,* the FASB issued ASU *2024*-*03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses.* The ASU requires companies to disaggregate operating expenses into specific categories such as employee compensation, depreciation, and intangible asset amortization, by relevant expense caption on the statement of operations. Additionally, in *January 2025,* the FASB issued ASU *2025*-*01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures*, to clarify the effective date of ASU *2024*-*03.* ASU *2025*-*01* is effective for fiscal years beginning after *December 15, 2026,* and interim periods within annual reporting periods beginning after *December 15, 2027,* on a retrospective or prospective basis, with early adoption permitted. The Company is currently evaluating the standard to determine the impact of adoption on its consolidated financial statements and disclosures.

***Other***

For further information regarding the Company's significant accounting policies, please refer to Note *2, Summary of Significant Accounting Policies* in the notes to the audited consolidated financial statements included in the section titled "Financial Statements and Supplementary Data" in Part II, Item *8* of the *2024* Annual Report on Form *10*-K. There were *no* material changes to the Company's critical accounting policies during the *nine* months ended *June 30, 2025*.

***3.* Discontinued Operations**

***Plan to Sell B Medical Systems Business***

During the *first* quarter of fiscal year *2025,* following approval by the Board of Directors of the Company, the Company publicly announced its plan to sell the B Medical Systems business. The B Medical Systems business operates as a separate business unit within the Company and focuses on the manufacturing and distribution of temperature-controlled storage and transportation solutions in international markets to governments, health institutions, and non-government organizations. This action is intended to simplify the Company's portfolio and allow management to focus on driving revenue growth and profitability in its core businesses. The decision followed work by the Board of Directors to evaluate strategic, operational and financial opportunities to maximize stockholder value. The Company anticipates entering into a definitive agreement to sell its B Medical Systems business by *November 2025.*

The Company determined that the B Medical Systems business met the "held for sale" criteria and "discontinued operations" criteria in accordance with FASB ASC *205* as of *November 12, 2024.* Results related to the B Medical Systems business are included within discontinued operations. The Condensed Consolidated Balance Sheet and Condensed Consolidated Statements of Operations, and the notes to the Condensed Consolidated Financial Statements, were retroactively reclassified for all periods presented to reflect the discontinuation of the B Medical Systems business in accordance with FASB ASC *205.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *14*

------

[**Table of Contents**](#toc)

The Company measured the B Medical Systems business at the lower of carrying value or fair value less cost to sell at each reporting period. During the *three* months ended *March 31, 2025,* the Company recorded $24 million of loss on assets held for sale based on the estimated fair value of the B Medical Systems business at that time. During the *three* months ended *June 30, 2025,* the Company recorded an additional $68.8 million of loss on assets held for sale due to subsequent changes in the fair value less costs to sell the business resulting from observable inputs received during the continued progression of the sale process. The loss on assets held for sale recorded during the *three* months ended *June 30, 2025* includes an immaterial correction of an error related to the *second* quarter of *2025,* whereby the Company had understated the loss recorded in the *second* quarter by $5.6 million, net of tax. The loss on assets held for sale is included in "Loss from discontinued operations, net of tax" on the Condensed Consolidated Statements of Operations for the *three* and *nine* months ended *June 30, 2025* and is included as a valuation allowance or contra-asset account within "Noncurrent assets held for sale" on the Condensed Consolidated Balance Sheets as of *June 30, 2025*.

The estimated fair value as of *March 31, 2025* was derived based on the income approach and the market approach which were weighted equally at *50%* each. The discounted cash flow method, or "DCF Method", was used in the income approach which reflected the Company's assumptions regarding revenue growth rates, forecasted gross profit margins, operating expenses, capital expenditures, discount rates, terminal period growth rates, economic and market trends, and other expectations about the anticipated operating results of the B Medical Systems business. The guideline company method was used in the market approach and publicly traded companies in similar lines of business were identified and used in an analysis to estimate the fair value. The fair value as of *March 31, 2025* was based on indications of the expected value of the business which is classified in level *3* of the fair value hierarchy due to the significance of unobservable inputs developed using company-specific information. The fair value as of *June 30, 2025* was based on observable inputs received during the continued progression of the sale process which is classified in level *2* of the fair value hierarchy.

The following table presents the financial results of the B Medical Systems business, included within discontinued operations (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Revenue |  |  |  |  |
| Products | $14333 | $24735 | $44507 | $54666 |
| Services | 1969 | 3782 | 6592 | 9222 |
| Total revenue | 16302 | 28517 | 51099 | 63888 |
| Cost of revenue |  |  |  |  |
| Products | 9793 | 21249 | 31333 | 48947 |
| Services | 1600 | 3690 | 6321 | 8873 |
| Total cost of revenue | 11393 | 24939 | 37654 | 57820 |
| Gross profit | 4909 | 3578 | 13445 | 6068 |
| Operating expenses |  |  |  |  |
| Research and development | 1533 | 1002 | 4369 | 3155 |
| Selling, general and administrative | 6939 | 9861 | 20855 | 27804 |
| Impairment of goodwill and intangible assets |  |  |  | 111317 |
| Loss on assets held for sale | 68838 |  | 93025 |  |
| Restructuring charges | 373 | 362 | 1051 | 4613 |
| Total operating expenses | 77683 | 11225 | 119300 | 146889 |
| Operating loss | (72774) | (7647) | (105855) | (140821) |
| Interest income (expense), net | (10) | 79 | (20) | 291 |
| Other income (expense), net | (92) | 94 | (166) | 776 |
| Loss before income taxes | (72876) | (7474) | (106041) | (139754) |
| Income tax benefit | (19689) | (1050) | (27044) | (4120) |
| Loss from discontinued operations, net of tax | $(53187) | $(6424) | $(78997) | $(135634) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *15*

------

[**Table of Contents**](#toc)

The following table presents the significant non-cash items and capital expenditures for the discontinued operations with respect to the B Medical Systems business that are included in the Condensed Consolidated Statements of Cash Flows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended June 30,*** | ***Three Months Ended June 30,*** | ***Nine Months Ended June 30,*** | ***Nine Months Ended June 30,*** |
|  | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| Depreciation and amortization | $- | $7907 | $3846 | $22859 |
| Capital expenditures | 1472 | 581 | 2600 | 2578 |
| Impairment of goodwill |  |  |  | 111317 |
| Loss on assets held for sale | 68838 |  | 93025 |  |

---

The carrying value of the assets and liabilities of the discontinued operations with respect to the B Medical Systems business reflected as "held for sale" on the Condensed Consolidated Balance Sheets as of *June 30, 2025* and *September 30, 2024* was as follows (in thousands):

---

| | | |
|:---|:---|:---|
|  | ***June 30, 2025*** | ***September 30, 2024*** |
| **<u>Assets</u>** |  |  |
| Cash and cash equivalents | $15000 | $30899 |
| Accounts receivable, net | 9566 | 16438 |
| Inventories | 45720 | 36333 |
| Prepaid expenses and other current assets | 6740 | 5224 |
| Current assets held for sale | $77025 | $88894 |
| Property, plant and equipment, net | $50490 | $47032 |
| Intangibles, net | 126130 | 122988 |
| Other assets | 5351 | 3774 |
| Valuation allowance | (96492) |  |
| Noncurrent assets held for sale | $85479 | $173794 |
| **<u>Liabilities</u>** |  |  |
| Accounts payable | $8587 | $11089 |
| Deferred revenue | 1639 | 1485 |
| Accrued warranty and retrofit costs | 5131 | 4916 |
| Accrued compensation and benefits | 3896 | 2929 |
| Accrued income taxes | 760 | 4012 |
| Accrued expenses and other current liabilities | 11702 | 5619 |
| Current liabilities held for sale | $31715 | $30050 |
| Long-term deferred tax liabilities | 11278 | 36093 |
| Long-term operating lease liabilities | 2852 | 2109 |
| Other long-term liabilities | 2961 | 3994 |
| Noncurrent liabilities held for sale | $17091 | $42196 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *16*

------

[**Table of Contents**](#toc)

***Disposition of Semiconductor Business***

On *February 1, 2022,* the Company completed the sale of the semiconductor automation business for $2.9 billion in cash to Thomas H. Lee Partners, L.P. On *July 1, 2019,* the Company completed the sale of the semiconductor cryogenics business for $659.8 million to Edwards Vacuum LLC (a member of the Atlas Copco Group) ("Edwards"). Both the semiconductor automation business and the semiconductor cryogenics business are considered discontinued operations. In the *third* quarter of fiscal year *2020,* Edwards asserted claims for indemnification under the definitive agreement relating to alleged breaches of representations and warranties relating to customer warranty claims and inventory (the *"2020* Claim"). In addition, in *January 2023,* Edwards filed a lawsuit against the Company in the Supreme Court of the State of New York in the County of New York seeking indemnification from the Company under such definitive agreement for $1.0 million and other related damages, including interest and attorney's fees, arising from a *third*-party claim that was included as part of their initial claims (the *"2023* Claim").

In *April 2023,* the Company responded to and filed a counterclaim against Edwards for the *2023* Claim alleging breach of the definitive agreements by Edwards and seeking a declaratory judgment. During the *third* quarter of fiscal year *2023,* the Company and Edwards entered into a settlement agreement related to the *2023* Claim to avoid the costs and uncertainties of potential litigation. Under the settlement agreement, the Company paid Edwards $0.8 million from *one* of the indemnification escrows established at closing of the sale in return for the release of the *2023* Claim and the release to the Company of $1.0 million from a separate indemnification escrow. The Company accrued a liability of $2.5 million for the *2020* Claim and *2023* Claim of which $0.8 million was paid during the *third* quarter of fiscal year *2023.* The Company accrued an additional liability of $0.4 million for the *2020* Claim during the *three* months ended *March 31, 2025* resulting in a total accrual of $2.1 million as of *June 30, 2025*.

The Company had been informed that Edwards sought recovery for the *2020* Claim from the representation and warranty insurance Edwards obtained in connection with the closing of the sale of the semiconductor cryogenics business. During the *first* quarter of fiscal year *2025,* the Company was further informed that Edwards agreed to a payment under such insurance for claimed amounts more than the applicable indemnification deductibles established under the definitive agreement, but less than the total of claimed amounts submitted for recovery. Although management believes that any indemnifiable losses in excess of the applicable deductibles established in the definitive agreement would have been covered by such insurance, and the Company further disputes any liability under applicable law, Edwards is seeking recovery from the Company for claimed amounts purportedly *not* covered, or inadequately covered, by such insurance (the "Claim for Uncovered Amounts"). The Company cannot determine the probability of any losses or outcome of the Claim for Uncovered Amounts including the amount of any indemnifiable losses, if any, resulting from this claim. The Company, however, does *not* believe that this claim will have a material adverse effect on its consolidated financial position or results of operations, in each case, for continuing operations. Any potential expense incurred by the Company for these claims would be reflected in discontinued operations.

In the event of unexpected subsequent developments and given the inherent unpredictability of these matters, there can be *no* assurance that the Company's assessment of these claims will reflect the ultimate outcome, and an adverse outcome in these matters could, from time to time, have a material adverse effect on the Company's consolidated financial position or results of operations in particular quarterly or annual periods.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *17*

------

[**Table of Contents**](#toc)

***4.* Marketable Securities** 

The Company had sales and maturities of marketable securities of $57.9 million and $241.0 million in the *three* months ended *June 30, 2025* and *2024*, respectively. The Company had sales and maturities of marketable securities of $242.5 million and $431.5 million in the *nine* months ended *June 30, 2025* and *2024*, respectively. There were immaterial realized gains or losses in each of the *three* and *nine* months ended *June 30, 2025* and *2024* on sales and maturities of marketable securities.

The following is a summary of the amortized cost and the fair value, including accrued interest receivable as well as unrealized gains (losses) on the short-term and long-term marketable securities as of *June 30, 2025* and *September 30, 2024* (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | ***Gross*** | ***Gross*** |  |
|  | ***Amortized*** | ***Unrealized*** | ***Unrealized*** |  |
|  | ***Cost*** | ***Losses*** | ***Gains*** | ***Fair Value*** |
| **June 30, 2025:** |  |  |  |  |
| U.S. Treasury securities and obligations of U.S. government agencies | $255091 | $(140) | $42 | $254993 |
| Bank certificates of deposit | 1234 |  |  | 1234 |
| Corporate securities | 3782 |  |  | 3782 |
| Municipal securities | 10932 |  | 44 | 10976 |
|  | $271039 | $(140) | $86 | $270985 |
| **September 30, 2024:** |  |  |  |  |
| U.S. Treasury securities and obligations of U.S. government agencies | $118159 | $(119) | $51 | $118091 |
| Bank certificates of deposit | 5212 | (13) | 1 | 5200 |
| Corporate securities | 77580 | (255) |  | 77325 |
|  | $200951 | $(387) | $52 | $200616 |

---

The amortized cost and fair value of the marketable securities by contractual maturities as of *June 30, 2025* are presented below (in thousands):

---

| | | |
|:---|:---|:---|
|  | ***Amortized*** |  |
|  | ***Cost*** | ***Fair Value*** |
| Due in one year or less | $48834 | $48817 |
| Due after one year through five years | 218423 | 218386 |
| Due after ten years | 3782 | 3782 |
| Total marketable securities | $271039 | $270985 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *18*

------

[**Table of Contents**](#toc)

Expected maturities could differ from contractual maturities because the security issuers *may* have the right to prepay obligations without prepayment penalties.

Unrealized losses from fixed-income securities are primarily attributable to changes in interest rates. The Company does *not* believe any unrealized losses represent impairments based on the evaluation of the available evidence.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

***5.* Derivative Instruments** 

The Company has transactions and balances denominated in currencies other than the functional currency of the transacting entity. Most of these transactions carry foreign exchange risk in Germany, the United Kingdom and China. The Company enters into foreign exchange contracts to reduce its exposure to currency fluctuations. Net gains and losses related to foreign exchange contracts are recorded as a component of "Other income, net" in the Condensed Consolidated Statements of Operations and were as follows for the *three* and *nine* months ended *June 30, 2025* and *2024* (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended*** | ***Three Months Ended*** | ***Nine Months Ended*** | ***Nine Months Ended*** |
|  | ***June 30,*** | ***June 30,*** | ***June 30,*** | ***June 30,*** |
|  | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| Realized losses on derivatives not designated as hedging instruments | $(4242) | $(415) | $(4246) | $(2202) |

---

The notional amounts of the Company's derivative instruments as of *June 30, 2025* and *September 30, 2024* were as follows (in thousands):

---

| | | | |
|:---|:---|:---|:---|
|  |  | **June 30,** | **September 30,**  |
|  | **Hedge Designation** | **2025** | **2024** |
| Cross-currency swap | *Net Investment Hedge* | $260025 | $75978 |
| Foreign exchange contracts | *Undesignated* | 46975 | 60101 |

---

The fair values of the foreign exchange contracts are recorded in the Condensed Consolidated Balance Sheets as "Prepaid expenses and other current assets" and "Accrued expenses and other current liabilities". Foreign exchange contract assets and liabilities are measured and reported at fair value based on observable market inputs and classified within Level *2* of the fair value hierarchy described further in Note *2, Summary of Significant Accounting Policies* in the notes to the audited consolidated financial statements included in the section titled "Financial Statements and Supplementary Data" in Part II, Item *8* of the *2024* Annual Report on Form *10*-K and in Note *12, Fair Value Measurements* below due to a lack of an active market for these contracts.

***Hedging Activities***

On *February 1, 2023,* the Company entered into a cross-currency swap agreement to hedge the variability of exchange rate impacts between the U.S. dollar and the Euro. Under the terms of the cross-currency swap agreement, the Company notionally exchanged $436.0 million for €400.0 million at a weighted average interest rate of 1.66%. The Company designated the cross-currency swap as a hedge of net investments against *one* of its Euro denominated subsidiaries, which requires an exchange at maturity of the notional amounts. At the maturity of the cross currency-swap on *February 1, 2024,* the Company delivered a notional amount of €400 million and received a notional amount of $436.0 million at a Euro to U.S. dollar exchange rate of 1.09, which included a gain of $1.4 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *19*

------

[**Table of Contents**](#toc)

On *February 1, 2024,* the Company entered into a cross-currency swap agreement to hedge the variability of exchange rate impacts between the U.S. dollar and the Euro. Under the terms of the cross-currency swap agreement, the Company notionally exchanged $76.0 million for €70.0 million at a weighted average interest rate of 1.44%. The Company designated the cross-currency swap as a hedge of net investments against *one* of its Euro denominated subsidiaries, which requires an exchange at maturity of the notional amounts. At the maturity of the cross currency-swap on *February 3, 2025,* the Company delivered a notional amount of €70.0 million and received a notional amount of $73.0 million at a Euro to U.S. dollar exchange rate of 1.0419, which included a gain of $3.0 million.

On *February 3, 2025,* the Company entered into another cross-currency swap agreement to hedge the variability of exchange rate impacts between the U.S. dollar and the Euro. Under the terms of the cross-currency swap agreement, the Company notionally exchanged $260.0 million for €250.0 million at a weighted average interest rate of 1.80%. The Company designated the cross-currency swap as a hedge of net investments against *one* of its Euro denominated subsidiaries, which requires an exchange of the notional amounts at maturity on *February 2, 2026.*

The cross-currency swaps were $34.7 million and $1.9 million and are recorded within a "Derivative liability" as of *June 30, 2025* and *September 30, 2024*, respectively, in the Condensed Consolidated Balance Sheets.

The outstanding cross-currency swap is marked to market at each reporting period, representing the fair value of the cross-currency swap, any changes in fair value are recognized as a component of "Accumulated other comprehensive loss" in the Condensed Consolidated Balance Sheets. The cross-currency swap is classified within Level *2* of the fair value hierarchy described in Note *2, Summary of Significant Accounting Policies* in the notes to the audited consolidated financial statements included in the section titled "Financial Statements and Supplementary Data" in Part II, Item *8* of the *2024* Annual Report on Form *10*-K and in Note *12, Fair Value Measurements* below.

Interest earned on the cross-currency swaps is recorded within "Interest income, net" in the Condensed Consolidated Statements of Operations. For the *three* months ended *June 30, 2025* and *2024*, the Company recorded interest income of $1.2 million and $0.3 million, respectively, on these instruments. For the *nine* months ended *June 30, 2025* and *2024*, the Company recorded interest income of $2.2 million and $3.4 million, respectively, on these instruments.

***6.* Goodwill and Intangible Assets** 

The Company conducts an impairment assessment annually on *April 1,* or more frequently if impairment indicators are present. The Company determined that a sustained decline in its stock price was an indicator of potential impairment and performed an interim quantitative goodwill impairment test for its reporting units as of *June 30, 2025.*

Based on the results of the interim quantitative impairment test performed as of *June 30, 2025,* the fair values of the Sample Management Solutions ("SMS") and Multiomics reporting units exceeded their respective carrying amounts. The Company concluded that there was *no* impairment to goodwill for the SMS and Multiomics reporting units as of *June 30, 2025.* The estimated fair value of each of the reporting units was derived based on the income approach and the market approach which were weighted at *75%* and *25%,* respectively, as of *June 30, 2025.* The DCF Method was used in the income approach which reflected the Company's assumptions regarding revenue growth rates, forecasted gross profit margins, operating expenses, capital expenditures, discount rates, terminal period growth rates, economic and market trends, and other expectations about the anticipated operating results of the SMS and Multiomics reporting units. The guideline company method was used in the market approach and publicly traded companies in similar lines of business were identified and used in an analysis to estimate the fair value.

Prior to the quantitative goodwill impairment test, the Company tested the recoverability of long-lived assets and other assets of the SMS and Multiomics reporting units and concluded that such assets were *not* impaired as of *June 30, 2025.*

The following table sets forth the changes in the carrying amount of goodwill by operating and reportable segment since *September 30, 2024* (in thousands).

---

| | | | |
|:---|:---|:---|:---|
|  | ***Sample*** |  |  |
|  | ***Management*** |  |  |
|  | ***Solutions*** | ***Multiomics*** | ***Total*** |
| Balance - October 1, 2024 | $494649 | $196760 | $691409 |
| Currency translation adjustments | 12205 |  | 12205 |
| Balance - June 30, 2025 | $506854 | $196760 | $703614 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *20*

------

[**Table of Contents**](#toc)

The components of the Company's identifiable intangible assets as of *June 30, 2025* and *September 30, 2024* are as follows (in thousands):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **June 30, 2025** | **June 30, 2025** | **June 30, 2025** | **September 30, 2024** | **September 30, 2024** | **September 30, 2024** |
|  |  | **Accumulated** | **Net Book** |  | **Accumulated** | **Net Book** |
|  | **Cost** | **Amortization** | **Value** | **Cost** | **Amortization** | **Value** |
| Patents | $1220 | $1220 | $— | $1227 | $1227 | $— |
| Completed technology | 111681 | 61411 | 50270 | 109949 | 55191 | 54758 |
| Trademarks and trade names | 734 | 271 | 463 | 726 | 195 | 531 |
| Customer relationships | 249203 | 191800 | 57403 | 248036 | 178283 | 69753 |
| Total | $362838 | $254702 | $108136 | $359938 | $234896 | $125042 |

---

Amortization expenses for intangible assets were $6.2 million and $7.2 million, respectively, for the *three* months ended *June 30, 2025* and *2024*. Amortization expenses for intangible assets were $18.4 million and $21.6 million, respectively, for the *nine* months ended *June 30, 2025* and *2024*.

Estimated future amortization expense for the intangible assets for the remainder of fiscal year *2025* and the subsequent *five* fiscal years are as follows (in thousands):

---

| | |
|:---|:---|
| Remainder of fiscal year 2025 | $6239 |
| 2026 | 22315 |
| 2027 | 17887 |
| 2028 | 15003 |
| 2029 | 12386 |
| 2030 | 10811 |

---

***7.* Restructuring** 

***2024* Restructuring Plan***

In the *second* quarter of fiscal year *2024,* the Company launched initiatives designed to optimize resources for future growth and improve efficiency across its organization. The focus of the initiatives is to improve the Company's profitability, which includes facilities consolidation, portfolio optimization, and organization structure simplification. The Company had additional restructuring actions during the *three* and *nine* months ended *June 30, 2025* under these initiatives and expects to complete the activities included in these initiatives by the end of fiscal year *2025.* As of the date of issuance of the accompanying Condensed Consolidated Financial Statements, the Company has *not* identified restructuring actions related to these initiatives that will result in additional material charges. The Company expects to identify additional actions as it further refines its plan, and the related initiatives in future periods will be recorded when specified criteria are met, including but *not* limited to, communication of benefit arrangements or when the costs have been incurred.

The majority of the restructuring expenses associated with the initiatives described above for the *three* and *nine* months ended *June 30, 2025* are severance and other related costs. Of the total restructuring expenses in the *three* months ended *June 30, 2025*, $0.3 million is related to the SMS segment and $0.4 million is related to the Multiomics segment. Of the total restructuring expenses in the *nine* months ended *June 30, 2025*, $1.9 million is related to the SMS segment, $2.1 million is related to the Multiomics segment, and $0.8 million is related to corporate.

The majority of restructuring expenses associated with the initiatives described above for the *three* and *nine* months ended *June 30, 2024* are severance and related costs and operating lease related right-of-use ("ROU") asset abandonment. Of the total restructuring expenses in the *three* and *nine* months ended *June 30, 2024*, $2.6 million is related to the SMS segment and $3.0 million is the Company's headquarters operating lease related ROU asset abandonment and corporate related severance costs.

***2023* Cost Savings Plans***

In the *second* and *third* quarters of fiscal year *2023,* the Company announced cost savings plans designed to position the Company to meet the needs of its customers and accelerate growth of the business. The cost savings plans were completed and costs from the actions were fully realized by the end of the *first* quarter of fiscal year *2024.* The restructuring expenses associated with the *2023* cost savings plans for the *three* and *nine* months ended *June 30, 2024* are severance and related costs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *21*

------

[**Table of Contents**](#toc)

The following table presents restructuring charges recognized for the *three* and *nine* months ended *June 30, 2025* and *2024* (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Severance and related costs | $971 | $852 | $4740 | $3625 |
| ROU asset abandonment |  |  |  | 901 |
| Other | (217) | 849 | 25 | 1389 |
| Total restructuring charges | $754 | $1701 | $4765 | $5915 |

---

The following table presents activity in the severance and related costs accruals for the *nine* months ended *June 30, 2025* and *2024* (in thousands):

---

| | | |
|:---|:---|:---|
|  | ***Nine Months Ended June 30,*** | ***Nine Months Ended June 30,*** |
|  | ***2025*** | ***2024*** |
| Balance at beginning of period | $755 | $665 |
| Provisions | 4740 | 3625 |
| Payments | (4637) | (3305) |
| Balance at end of period | $858 | $985 |

---

***8.* Supplementary Balance Sheet Information**

***Inventories***

The following is a summary of inventories at *June 30, 2025* and *September 30, 2024* (in thousands):

---

| | | |
|:---|:---|:---|
|  | ***June 30,*** | ***September 30,*** |
|  | ***2025*** | ***2024*** |
| Raw materials and purchased parts | $35796 | $34134 |
| Work-in-process | 6056 | 8402 |
| Finished goods | 38654 | 36387 |
| Total inventories | $80506 | $78923 |

---

Inventory reserves were $8.5 million and $6.1 million, respectively, at *June 30, 2025* and *September 30, 2024*.

***Warranty and Retrofit Costs***

The following is a summary of product and warranty retrofit activity for the *nine* months ended *June 30, 2025* and *2024* (in thousands):

---

| | | |
|:---|:---|:---|
|  | ***Nine Months Ended June 30,*** | ***Nine Months Ended June 30,*** |
|  | ***2025*** | ***2024*** |
| Balance at beginning of period | $5213 | $3974 |
| Accruals for warranties during the period | 587 | 1939 |
| Costs incurred during the period | (427) | (1184) |
| Balance at end of period | $5373 | $4729 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *22*

------

[**Table of Contents**](#toc)

***9.* Stockholders**' **Equity**

***Share Repurchases***

On *November 4, 2022,* the Company's Board of Directors approved an authorization to repurchase up to $1.5 billion of the Company's common stock (the *"2022* Repurchase Authorization"). During the *nine* months ended *June 30, 2024*, the Company repurchased 3.5 million shares of common stock for $186.8 million (excluding fees, commissions, and excise tax) under this authorization. As of *September 30, 2024,* the Company had repurchased and retired 30.0 million shares of common stock for the full $1.5 billion approved under the *2022* Repurchase Authorization. All shares repurchased under the *2022* Repurchase Authorization were retired, accounted for as a reduction to stockholders' equity in the Condensed Consolidated Balance Sheets and treated as a repurchase of common stock for purposes of calculating earnings per share as of the applicable settlement dates. *No* additional repurchase authorization has been approved and as such there were no shares repurchased during the *nine* months ended *June 30, 2025*.

Effective *January 1, 2023,* all corporate share repurchases are subject to a *one* percent U.S. excise tax on the value of the repurchase, net of share issuances, subject to certain exclusions. The Company's accrual for excise tax related to share repurchases is considered an additional cost of the share repurchases and a reduction to stockholders' equity in the Condensed Consolidated Balance Sheets. During the *nine* months ended *June 30, 2025*, the Company paid the remaining excise tax due in connection with the *2022* Repurchase Authorization, totaling $11.4 million.

***Accumulated Other Comprehensive Income (Loss)***

The following is a summary of the components of accumulated other comprehensive income (loss), net of tax for the *nine* months ended *June 30, 2025* and *2024* (in thousands):

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  | ***Unrealized*** |  |  |  |
|  |  | ***Gains (Losses)*** |  |  |  |
|  |  | ***on Available-*** |  | ***Pension*** |  |
|  | ***Currency*** | ***for-Sale*** | ***Gains (Losses)*** | ***Liability*** |  |
|  | ***Translation*** | ***Securities*** | ***on Derivative*** | ***Adjustments*** |  |
|  | ***Adjustments*** | ***Net of tax*** | ***Net of tax*** | ***Net of tax*** | ***Total*** |
| Balance at September 30, 2023 | $(88448) | $(5135) | $31487 | $(330) | $(62426) |
| Other comprehensive income (loss) before reclassifications | 21725 | 3799 | (7971) | (88) | 17465 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amounts reclassified from accumulated other comprehensive income (loss) |  |  |  | 66 | 66 |
| Balance at June 30, 2024 | $(66723) | $(1336) | $23516 | $(352) | $(44895) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *23*

------

[**Table of Contents**](#toc)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  | ***Unrealized*** |  |  |  |
|  |  | ***Gains (Losses)*** |  |  |  |
|  |  | ***on Available-*** |  | ***Pension*** |  |
|  | ***Currency*** | ***for-Sale*** | ***Gains (Losses)*** | ***Liability*** |  |
|  | ***Translation*** | ***Securities*** | ***on Derivative*** | ***Adjustments*** |  |
|  | ***Adjustments*** | ***Net of tax*** | ***Net of tax*** | ***Net of tax*** | ***Total*** |
| Balance at September 30, 2024 | $(34170) | $(263) | $21468 | $(499) | $(13464) |
| Other comprehensive income (loss) before reclassifications | 33462 | 262 | (39744) | (205) | (6225) |
| Amounts reclassified from accumulated other comprehensive income (loss) |  |  |  | 54 | 54 |
| Balance at June 30, 2025 | $(708) | $(1) | $(18276) | $(650) | $(19635) |

---

As described in Note *2, Summary of Significant Accounting Policies* in the notes to the audited consolidated financial statements included in the section titled "Financial Statements and Supplementary Data" in Part II, Item *8* of the *2024* Annual Report on Form *10*-K, unrealized gains (losses) on available-for-sale marketable securities are reclassified from "Accumulated other comprehensive income (loss)" into results of operations at the time of the securities' sale, gains (losses) on derivative are the effective portions of changes in the fair value of the net investment hedges which are recorded in "Accumulated other comprehensive income (loss)", and amounts reclassified from "Accumulated other comprehensive income (loss)" related to pension liability adjustments represent amortization of actuarial gains and losses.

***10.* Revenue from Contracts with Customers**

***Disaggregated Revenue***

The Company disaggregates revenue from contracts with customers in a manner that depicts how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors. The following is revenue by significant business line for the *three* and *nine* months ended *June 30, 2025* and *2024* (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three months ended June 30,*** | ***Three months ended June 30,*** | ***Nine months ended June 30,*** | ***Nine months ended June 30,*** |
|  | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| **Significant Business Line** |  |  |  |  |
| Multiomics | $66235 | $63619 | $196054 | $188556 |
| Core Products <sup>(1)</sup> | 45750 | 49440 | 143418 | 143170 |
| Sample Repository Services | 31957 | 31233 | 95398 | 90646 |
| Total revenue | $143942 | $144292 | $434870 | $422372 |

---

*(*1*) Core Products are Automated Stores, Cryogenic Systems, Automated Sample Tube, Consumables and Instruments and Controlled Rate Thawing Devices.* 

***Contract Balances***

*Accounts Receivable, Net.* Accounts receivable represent rights to consideration in exchange for products or services that have been transferred by the Company, when payment is unconditional and only the passage of time is required before payment is due. Accounts receivable do *not* bear interest and are recorded at the invoiced amount. The Company maintains an allowance for expected credit losses representing its best estimate of probable credit losses related to its existing accounts receivable and their net realizable value. The Company determines the allowance for expected credit losses based on a number of factors, including an evaluation of customer credit worthiness, the age of the outstanding receivables, economic trends, historical experience, and other information through the payment periods. Accounts receivable, net were $124.5 million and $156.3 million at *June 30, 2025* and *September 30, 2024*, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *24*

------

[**Table of Contents**](#toc)

*Contract Assets.* Contract assets represent rights to consideration in exchange for products or services that have been transferred by the Company and payment is conditional on something other than the passage of time. These amounts typically relate to contracts where the right to invoice the customer is *not* present until completion of the contract or the achievement of specified milestones and the value of the products or services transferred exceed this constraint. Contract assets are classified as current as they are expected to convert to cash within *one* year. Contract asset balances which are included within "Prepaid expenses and other current assets" in the Condensed Consolidated Balance Sheet, were $40.1 million and $28.9 million at *June 30, 2025* and *September 30, 2024*, respectively. Revenue of $49.4 million and $34.0 million recognized, respectively, during the *nine* months ended *June 30, 2025* and *2024* contributed to the contract asset balances at *June 30, 2025* and *June 30, 2024*, respectively.

*Contract Liabilities.* Contract liabilities represent the Company's obligation to transfer products or services to a customer for which consideration has been received, or for which an amount of consideration is due from the customer. Contract assets and liabilities are reported on a net basis at the contract level, depending on the contract's position at the end of each reporting period. Contract liabilities are included within "Deferred revenue" in the Condensed Consolidated Balance Sheet. Contract liabilities were $40.0 million and $30.5 million at *June 30, 2025* and *September 30, 2024*, respectively. The Company recognized revenues of $19.0 million and $29.0 million in the *nine* months ended *June 30, 2025* and *2024*, respectively, that were included in the contract liability balance at the beginning of each period*.*

*Remaining Performance Obligations.* Remaining performance obligations represent the transaction price of unsatisfied or partially satisfied performance obligations within contracts with an original expected contract term that is greater than *one* year and for which fulfillment of the contract has started as of the end of the reporting period. The aggregate amount of transaction consideration allocated to remaining performance obligations as of *June 30, 2025* was $76.2 million. The following table summarizes when the Company expects to recognize the remaining performance obligations as revenue; the Company will recognize revenue associated with these performance obligations as transfer of control occurs (in thousands):

---

| | | | |
|:---|:---|:---|:---|
|  | ***As of June 30, 2025*** | ***As of June 30, 2025*** | ***As of June 30, 2025*** |
|  | ***Less than 1 Year*** | ***Greater than 1 Year*** | ***Total*** |
| Remaining performance obligations | $55236 | $20968 | $76204 |

---

***11.* Stock-Based Compensation** 

In accordance with the Company's *2020* Equity Incentive Plan, the Company *may* issue to eligible employees options to purchase shares of the Company's common stock, restricted stock units and other equity incentives which vest upon the satisfaction of a performance condition and/or a service condition. In addition, the Company issues common stock to participating employees pursuant to an employee stock purchase plan, and *may* issue common stock awards and deferred restricted stock units to members of its Board of Directors in accordance with its Board of Director compensation program.

***2020* Equity Incentive Plan***

The following table reflects the total stock-based compensation expense for continuing operations recorded during the *three* and *nine* months ended *June 30, 2025* and *2024* (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended June 30,*** | ***Three Months Ended June 30,*** | ***Nine Months Ended June 30,*** | ***Nine Months Ended June 30,*** |
|  | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| Restricted stock units | $1973 | $3381 | $14408 | $11122 |
| Employee stock purchase plan | 242 | 310 | 711 | 980 |
| Total stock-based compensation expense | $2215 | $3691 | $15119 | $12102 |

---

The Company recorded $0.2 million and $0.1 million of stock-based compensation expense for discontinued operations during the *three* months ended *June 30, 2025* and *2024*, respectively, and $0.8 million and $0.5 million of stock-based compensation expense for discontinued operations during the *nine* months ended *June 30, 2025* and *2024*, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *25*

------

[**Table of Contents**](#toc)

***Restricted Stock Unit Activity***

The following table summarizes restricted stock unit activity for the *nine* months ended *June 30, 2025*:

---

| | | |
|:---|:---|:---|
|  |  | ***Weighted*** |
|  |  | ***Average*** |
|  |  | ***Grant-Date*** |
|  | ***Shares*** | ***Fair Value*** |
| Outstanding as of September 30, 2024 | 764111 | $59.65 |
| Granted | 641843 | $45.00 |
| Vested | (188605) | $59.13 |
| Forfeited | (131421) | $73.80 |
| Outstanding as of June 30, 2025 | 1085928 | $49.38 |

---

Awards vested during the *nine* months ended *June 30, 2025* per the table above include 9,209 shares for discontinued operations. The fair value of restricted stock units vested during the *nine* months ended *June 30, 2025* was $7.7 million for continuing operations.

As of *June 30, 2025*, the future unrecognized stock-based compensation expense related to restricted stock units for continuing operations expected to vest is $25.5 million and is expected to be recognized over an estimated weighted average amortization period of 1.7 years.

Restricted stock units granted with performance goals *may* also have a required service period following the achievement of all or a portion of the performance goals. The following table reflects restricted stock units granted during the *nine* months ended *June 30, 2025* and *2024*:

---

| | | |
|:---|:---|:---|
|  | ***Nine Months Ended June 30,*** | ***Nine Months Ended June 30,*** |
|  | ***2025*** | ***2024*** |
| Time-based restricted stock units | 448375 | 220641 |
| Performance-based restricted stock units | 193468 | 389933 |
| Total units | 641843 | 610574 |

---

All restricted stock units granted during the *nine* months ended *June 30, 2025* included in the table above relate to continuing operations. Restricted stock units granted during the *nine* months ended *June 30, 2024* included in the table above include 31,475 units related to discontinued operations.

***Time-Based Restricted Stock Unit Grants***

Restricted stock units granted with a required service period typically have *three*-year vesting schedules in which one-*third* of awards vest at each annual anniversary of grant date, subject to the award holders meeting service requirements.

***Performance-Based Restricted Stock Unit Grants***

Performance-based restricted stock units are earned based on the achievement of performance criteria established by the Human Resources and Compensation Committee and approved by the Company's Board of Directors. The criteria for performance-based awards are weighted and have threshold, target, and maximum performance goals.

In *October 2023,* the Company's Board of Directors approved an amendment to the performance goals associated with the previously issued performance-based restricted stock units for all impacted employees, excluding members of the executive team. The performance goals, as amended, are more reflective of the current macroeconomic environment and consideration toward employee retention in the competitive life sciences industry. Before the amendment, the original performance goals were *not* expected to be satisfied. Subsequent to the amendment, vesting became probable based on the forecasted achievement of the amended performance goals. The amendment of these restricted stock units is treated as a modification with the total potential maximum compensation cost of $3.3 million recognized over the service period through *November 2025.* The Company recorded expense of $0.1 million and $1.0 million in the *three* and *nine* months ended *June 30, 2025*, respectively, related to the modified awards.

These performance-based restricted stock unit awards granted allow participants to earn 100% of restricted stock units if the Company's performance meets or exceeds its target goal for each applicable financial metric, and up to a maximum of 200% if the Company's performance for such metrics meets or exceeds the maximum or stretch goal. Performance below the minimum threshold for each financial metric results in award forfeiture. Performance goals are measured over a three-year period for each year's restricted stock unit awards and at the end of the period to determine the number of restricted stock units earned, if any, by recipients who continue to meet the service requirement. Upon the *third* anniversary of each year's restricted stock unit awards' grant date, the Company's Board of Directors approves the number of restricted stock units earned for participants who continue to meet the service requirements on the vesting date. For restricted stock unit awards that include vesting based on performance conditions, the fair values are estimated based on the intrinsic values of the awards at the grant date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *26*

------

[**Table of Contents**](#toc)

In *November 2024,* the Company issued restricted stock unit awards with vesting based on market conditions, which will vest based on achievement of the Company's relative total shareholder return against the defined peer group over a *three*-year period. The fair values for those grants that include vesting based on market conditions are estimated using the Monte Carlo simulation model. The key assumptions used in the Monte Carlo simulation included (i) the expected volatility based on the *three*-year daily historical volatility as measured on the grant date, (ii) risk-free interest rate based on U.S. Treasury constant maturities yields as of the grant date, (iii) correlation assumption based on daily share price changes over *three* years between the Company and the peer companies measured on the grant date, and (iv) *no* expected dividend yield.

***12.* Fair Value Measurements**

See Note *2, Summary of Significant Accounting Policies* in the notes to the audited consolidated financial statements included in the section titled "Financial Statements and Supplementary Data" in Part II, Item *8* of the *2024* Annual Report on Form *10*-K for information on the fair value hierarchy and the level of inputs used by the Company in determining fair value.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *27*

------

[**Table of Contents**](#toc)

***Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis***

The following tables summarize assets and liabilities measured and recorded at fair value on a recurring basis in the Condensed Consolidated Balance Sheets as of *June 30, 2025* and *September 30, 2024* (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **As of June 30, 2025** | **As of June 30, 2025** | **As of June 30, 2025** | **As of June 30, 2025** |
| **Description** | **Total Fair Value** | **Level 1** | **Level 2** | **Level 3** |
| Assets: |  |  |  |  |
| Cash equivalents | $141537 | $141035 | $502 | $— |
| Available-for-sale securities | 270985 | 9447 | 261538 |  |
| Investment in equity securities | 2100 |  |  | 2100 |
| Foreign exchange contracts | 142 |  | 142 |  |
| Total assets | $414764 | $150482 | $262182 | $2100 |
| Liabilities: |  |  |  |  |
| Net investment hedge | 34656 |  | 34656 |  |
| Total liabilities | $34656 | $— | $34656 | $— |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***As of September 30, 2024*** | ***As of September 30, 2024*** | ***As of September 30, 2024*** | ***As of September 30, 2024*** |
| **Description** | ***Total Fair Value*** | ***Level 1*** | ***Level 2*** | ***Level 3*** |
| Assets: |  |  |  |  |
| Cash equivalents | $157990 | $157990 | $— | $— |
| Available-for-sale securities | 198616 | 37584 | 161032 |  |
| Convertible debt securities | 2000 |  |  | 2000 |
| Foreign exchange contracts | 9 |  | 9 |  |
| Total assets | $358615 | $195574 | $161041 | $2000 |
| Liabilities: |  |  |  |  |
| Net investment hedge | 1915 |  | 1915 |  |
| Foreign exchange contracts | 213 |  | 213 |  |
| Total liabilities | $2128 | $— | $2128 | $— |

---

***Cash Equivalents***

The Company considers all highly liquid interest-earning investments with a maturity of *three* months or less at the date of purchase to be cash equivalents. Cash equivalents primarily consist of money market funds and U.S. government backed securities with a maturity of *three* months or less. They are classified as Level *1* because they are valued using quoted market prices in active markets. The fair values of these investments approximate their carrying values. Investments classified as Level *2* consist of debt securities valued using matrix pricing benchmarking because they are *not* actively traded and bank certificates of deposit with a maturity of *three* months or less. Matrix pricing is a mathematical technique used to value securities by relying on the securities' relationship to other benchmark quoted prices.

***Available-For-Sale Securities***

Available-for-sale securities primarily consist of highly rated corporate debt securities, and U.S. government backed securities, which are classified as Level *1.* Investments classified as Level *2* consist of debt securities that are valued using matrix pricing and benchmarking because they are *not* actively traded, and bank certificates of deposit.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *28*

------

[**Table of Contents**](#toc)

***Convertible Debt Securities and Investment in Equity Securities***

In the *third* quarter of fiscal year *2024,* the Company purchased $2.0 million principal amount of convertible notes issued by a private company. The Company accounted for the investment in these convertible notes at fair value with changes in fair value recognized in the Condensed Consolidated Statement of Operations. As of the conversion of these notes into preferred stock of the private company described below, the fair value of the convertible notes was $2.1 million.

During the *first* quarter of fiscal year *2025,* the Company converted the convertible notes into 420,000 shares of preferred stock of the private company. The conversion did *not* result in the recognition of additional gain or loss on the convertible notes. The shares of preferred stock are equity securities and within the scope of ASC *321, Investments - Equity Securities*. The Company elected the measurement alternative for its investment in the shares of preferred stock because the shares do *not* have a readily determinable fair value. As of *June 30, 2025*, the carrying value of the investment in the shares of preferred stock was $2.1 million and is included in "Other assets" on the Condensed Consolidated Balance Sheets. The fair value determination is classified as Level *3* based on unobservable inputs which were based on the best information available in the circumstance, including transaction pricing, recent acquisition, and market participant assumptions. The unobservable inputs used in the determination of the fair value of assets classified as Level *3* have an inherent measurement uncertainty that if changed could result in higher or lower fair value measurements of the assets as of the reporting date.

***Foreign Exchange Contracts & Net Investment Hedge***

The Company's foreign exchange contract assets and liabilities, and its net investment hedge assets are measured and reported at fair value using the market method valuation technique. The inputs to this technique utilize current foreign currency exchange forward market rates published by *third*-party leading financial news and data providers. These are observable data that represent the rates that the financial institution uses for contracts entered into at that date; however, they are *not* based on actual transactions, so they are classified as Level *2.*

***Financial Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis***

During the *three* and *nine* months ended *June 30, 2025* and *2024*, the Company did not record any material other-than-temporary impairments on financial assets required to be measured at fair value on a nonrecurring basis.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *29*

------

[**Table of Contents**](#toc)

***13.* Income Taxes**

The Company recorded income tax expense of $2.8 million and $14.0 million during the *three* and *nine* months ended *June 30, 2025*, respectively. The tax expense for the *nine* months ended *June 30, 2025* was primarily driven by a $6.5 million tax expense related to a change in the indefinite reinvestment assertion and the repatriation of cash to the United States from a China subsidiary. The tax expense is also driven by profits in foreign jurisdictions and current state income taxes in jurisdictions where the Company does *not* have a net operating loss carryover. Additionally, tax expense is generated on a global loss because the Company does *not* benefit from the U.S. tax loss due to a valuation allowance against U.S. deferred tax assets.

The Company recorded an income tax expense of $0.6 million and $3.2 million during the *three* and *nine* months ended *June 30, 2024,* respectively. The tax expense was primarily driven by a $1.7 million charge related to a valuation allowance recorded against deferred tax assets in a foreign subsidiary during the *three* months ended *March 31, 2024.* Tax expense also includes $0.5 million of stock compensation shortfall expense for tax deductions that were lower than the associated book compensation expense during the *nine* months ended *June 30, 2024* and $0.7 million of expenses related to a valuation allowance on beginning of year U.S. state deferred tax assets.

The Company evaluates the realizability of its deferred tax assets and assesses the need for a valuation allowance on a quarterly basis. The Company operates in numerous countries under many legal forms and, as a result, is subject to the jurisdiction of numerous domestic and foreign tax authorities. The Company evaluates the profitability of its operations in each jurisdiction on a historic cumulative basis and on a forward-looking basis, while carefully considering carry-forward periods of tax attributes and ongoing tax planning strategies in assessing the need for the valuation allowance.

The Company has generated U.S. pre-tax losses in recent years and provided a valuation allowance against U.S. deferred tax assets during fiscal year *2024.* The Company expects to generate a U.S. book loss during fiscal year *2025* and expects a valuation allowance of $22 million in the United States against its net deferred tax assets for fiscal year *2025.*

The Company also maintains a valuation allowance against net deferred tax assets on certain foreign tax-paying components.

The Company provided deferred income taxes of $6.5 million during the *three* months ended *March 31, 2025* related to a change in the indefinite reinvestment assertion for its operations in China on $62 million of unremitted earnings. The $62 million of earnings represents a partial repatriation on distributable profits earned through *December 31, 2024.* As of *June 30, 2025,* $34 million of these earnings have been remitted to the United States. The tax expense is driven by foreign withholding taxes and state income taxes. The Company maintains its general assertion of indefinite reinvestment on the remaining unremitted foreign earnings for China beyond *December 31, 2024* and for other foreign jurisdictions.

The Company maintains liabilities for unrecognized tax benefits based on its estimates and assumptions. The Company recognizes interest related to unrecognized tax benefits as a component of the income tax provision or benefit. The Company recognized minimal interest expense related to its unrecognized tax benefits during the *three* and *nine* months ended *June 30, 2025*.

The Company is subject to U.S. federal, state, local and foreign income taxes in various jurisdictions. The amount of income taxes paid is subject to the Company's interpretation of applicable tax laws in the jurisdictions in which it files.

In the normal course of business, the Company is subject to income tax audits in various global jurisdictions in which it operates. The years subject to examination vary for the United States and international jurisdictions, with the earliest tax year being 2018. Based on the outcome of these examinations or the expiration of statutes of limitations for specific jurisdictions, it is reasonably possible that the related unrecognized tax benefits could change from those recorded in the Condensed Consolidated Balance Sheets. The Company currently anticipates that it is reasonably possible that the unrecognized tax benefits and accrued interest on those benefits will *not* be reduced in the next *twelve* months due to the statute of limitations expirations. These unrecognized tax benefits would impact the effective tax rate if recognized.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *30*

------

[**Table of Contents**](#toc)

***14.* Net Income (Loss) per Share**

The calculations of basic and diluted net income (loss) per share and basic and diluted weighted average shares outstanding are as follows for the *three* and *nine* months ended *June 30, 2025* and *2024* (in thousands, except per share data):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended**  | **Three Months Ended**  | **Nine Months Ended** | **Nine Months Ended** |
|  | **June 30,** | **June 30,** | **June 30,** | **June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Income (loss) from continuing operations | $680 | $(158) | $(26926) | $(23552) |
| Loss from discontinued operations, net of tax | (53486) | (6424) | (79676) | (135634) |
| Net loss | $(52806) | $(6582) | $(106602) | $(159186) |
| Weighted average common shares outstanding used in computing basic income (loss) per share | 45780 | 52963 | 45712 | 54914 |
| Dilutive restricted stock units | 43 |  |  |  |
| Weighted average common shares outstanding used in computing diluted income (loss) per share | 45823 | 52963 | 45712 | 54914 |
| Basic net income (loss) per share: |  |  |  |  |
| Income (loss) from continuing operations | $0.01 | $(0.00) | $(0.59) | $(0.43) |
| Loss from discontinued operations, net of tax | $(1.17) | $(0.12) | $(1.74) | $(2.47) |
| Basic net loss per share | $(1.15) | $(0.12) | $(2.33) | $(2.90) |
| Diluted net income (loss) per share: |  |  |  |  |
| Income (loss) from continuing operations | $0.01 | $(0.00) | $(0.59) | $(0.43) |
| Loss from discontinued operations, net of tax | $(1.17) | $(0.12) | $(1.74) | $(2.47) |
| Diluted net loss per share | $(1.15) | $(0.12) | $(2.33) | $(2.90) |

---

For the *three* months ended *June 30, 2025*, unvested restricted stock and performance stock units representing 753,065 shares were excluded from the computation of diluted income per share from continuing operations as their inclusion would have been antidilutive. For the *nine* months ended *June 30, 2025* and *three* and *nine* months ended *June 30, 2024*, outstanding restricted stock units and shares issued by the Company under the employee stock purchase plan representing 137,306 shares, 102,252 shares and 138,273 shares, respectively, were excluded from the computation of diluted loss per share as their inclusion would have been antidilutive.

***15.* Segment and Geographic Information**

Operating segments are defined as components of an enterprise that engage in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker ("CODM") in deciding how to allocate resources and to assess performance. The Company's Chief Executive Officer is the Company's CODM.

As of *November 12, 2024,* the Company's B Medical Systems business met the "held for sale" criteria and "discontinued operations" criteria in accordance with FASB ASC *205* and the results of the B Medical Systems business are included within discontinued operations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *31*

------

[**Table of Contents**](#toc)

The Company's continuing operations includes the following operating and reportable segments:

● **Sample Management Solutions**. The SMS business resources operate as a single business unit offering end-to-end sample management products and services, including: Sample Repository Services and Core Products (Automated Stores, Cryogenic Systems, Automated Sample Tube, Consumables and Instruments and Controlled Rate Thawing Devices).

● **Multiomics**. The Multiomics business resources operate as a single business unit offering genomic and other sample analysis services, including gene sequencing and gene synthesis.

Management considers adjusted operating income (loss), which excludes charges related to amortization of intangible assets, transformation costs, restructuring charges, goodwill and intangible asset impairment, merger and acquisition costs, costs related to share repurchase and governance-related matters, and other unallocated corporate expenses, as the primary performance metric when evaluating each segment's operations.

The following is the summary of the financial information for the Company's operating and reportable segments for the *three* and *nine* months ended *June 30, 2025* and *2024* (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended June 30,*** | ***Three Months Ended June 30,*** | ***Nine Months Ended June 30,*** | ***Nine Months Ended June 30,*** |
|  | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| **Revenue:** |  |  |  |  |
| Sample Management Solutions | $77707 | $80673 | $238816 | $233816 |
| Multiomics | 66235 | 63619 | 196054 | 188556 |
| Total revenue | $143942 | $144292 | $434870 | $422372 |
| **Adjusted operating income (loss):** |  |  |  |  |
| Sample Management Solutions | $11248 | $3582 | $18177 | $1509 |
| Multiomics | (3331) | (592) | (11127) | (6736) |
| Segment adjusted operating loss | 7917 | 2990 | 7050 | (5227) |
| Amortization of completed technology | 2068 | 2047 | 5876 | 5970 |
| Amortization of other intangible assets | 4123 | 5132 | 12499 | 15655 |
| Transformation costs <sup>(1)</sup> | 1542 | 1174 | 9771 | 5310 |
| Restructuring charges | 754 | 1701 | 4765 | 5915 |
| Impairment of intangible assets |  |  |  | 4658 |
| Merger and acquisition costs and costs related to share repurchase <sup>(2)</sup> | 58 | 74 | 2316 | 4821 |
| Other unallocated corporate adjustments | 86 | (32) | 41 | 8 |
| Total operating loss | (714) | (7106) | (28218) | (47564) |
| Interest income, net | 4973 | 7925 | 13760 | 27359 |
| Other income (expense), net | (821) | (377) | 1539 | (127) |
| Income (loss) before income taxes | $3438 | $442 | $(12919) | $(20332) |

---

(*1*) Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do *not* meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's *2024* transformation plan and primarily relate to *one* time asset write downs associated with changes in technology, *one*-time inventory write downs relating to restructuring actions taken in the period, and *third*-party consulting costs associated with process and systems re-design.

(*2*) Includes expenses related to governance-related matters.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *32*

------

[**Table of Contents**](#toc)

The following is the summary of the asset information for the Company's reportable segments as of *June 30, 2025* and *September 30, 2024* (in thousands):

---

| | | |
|:---|:---|:---|
| **Assets:** | **June 30, 2025** | **September 30, 2024** |
| Sample Management Solutions | $853347 | $859353 |
| Multiomics | 445337 | 462825 |
| Total assets | $1298684 | $1322178 |

---

The following is a reconciliation of the segment assets to the corresponding amounts presented in the Condensed Consolidated Balance Sheets as of *June 30, 2025* and *September 30, 2024* (in thousands):

---

| | | |
|:---|:---|:---|
|  | **June 30,** | **September 30,** |
|  | **2025** | **2024** |
| Segment assets | $1298684 | $1322178 |
| Cash and cash equivalents, restricted cash and marketable securities | 549801 | 490707 |
| Deferred tax assets | 779 | 837 |
| General corporate assets | 7367 | 23631 |
| Assets held for sale | 162504 | 262688 |
| Total assets | $2019135 | $2100041 |

---

Revenue from external customers is attributed to geographic areas based on locations in which the product is shipped. Net revenue by geographic area for the *three* and *nine* months ended *June 30, 2025* and *2024* are as follows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| **Geographic Location:** |  |  |  |  |
| United States | $87833 | $95037 | $271244 | $272898 |
| China | 14321 | 14510 | 41947 | 43054 |
| United Kingdom | 9370 | 8086 | 25252 | 19387 |
| Rest of Europe | 25430 | 21370 | 75009 | 66493 |
| Asia Pacific/Other | 6988 | 5289 | 21418 | 20540 |
| Total revenue | $143942 | $144292 | $434870 | $422372 |

---

For the *three* and *nine* months ended *June 30, 2025* and *2024*, the Company did not have any individual customers that accounted for *10%* or more of its consolidated revenue. As of *June 30, 2025* and *September 30, 2024*, there were no customers that accounted for more than *10%* of the Company's accounts receivable balance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *33*

------

[**Table of Contents**](#toc)

***16.* Commitments and Contingencies**

***Contingencies***

The Company is subject to various legal proceedings, both asserted and unasserted, that arise in the ordinary course of business. The Company cannot predict the ultimate outcome of such legal proceedings or, in certain instances, provide reasonable ranges of potential losses. The Company considers all claims on a quarterly basis and based on known facts assesses whether potential losses are considered reasonably possible, probable, and estimable. Based upon this assessment, the Company then evaluates disclosure requirements and whether to accrue for such claims in the Condensed Consolidated Financial Statements. At *June 30, 2025* and as of the date of filing of these Condensed Consolidated Financial Statements, the Company believes that *no* new material provision for liability nor new disclosure is required related to any claims. In the event of unexpected subsequent developments and given the inherent unpredictability of these matters, there can be *no* assurance that the Company's assessment of any claim will reflect the ultimate outcome, and an adverse outcome in certain matters could, from time to time, have a material adverse effect on the Company's consolidated financial position or results of operations in particular quarterly or annual periods.

***Tariff Matter***

With the assistance of a *third*-party consultant, during the *first* quarter of fiscal year *2021,* the Company initiated a review of the value of transactions it used for intercompany imports into the United States from its GENEWIZ business. As a result of this review and an interpretation surrounding the valuation method used to calculate the estimated transaction value, the Company revised its estimate of the tariffs owed and paid $5.9 million to U.S. customs authorities in fiscal year *2022* related to transactions prior to *December 2021.* In *July 2024,* the Company paid approximately $2.5 million in tariffs as well as interest related to the imports from its GENEWIZ business into the United States during the period from *December 2021* to *July 2024.* As of *June 30, 2025*, the Company does *not* anticipate any penalties associated with this payment because its valuation methodology was accepted by U.S. customs authorities during previous voluntary disclosures. The Company expects that the U.S. customs authorities will issue the final audit results for these periods by the end of the *fourth* quarter of fiscal year *2025.*

***Purchase Commitments***

As of *June 30, 2025*, the Company had non-cancellable commitments of $48.7 million, comprised of purchase orders for inventory of $37.3 million and other operating expense commitments of $11.4 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *34*

------

[**Table of Contents**](#toc)

**Item 2. *Management***'***s Discussion and Analysis of Financial Condition and Results of Operations***

You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited interim condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and the audited financial statements and related notes contained in the 2024 Annual Report on Form 10-K. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below and in the forward-looking statements. Factors that could cause or contribute to these differences include, without limitation, those discussed in this Management's Discussion and Analysis of Financial Condition and Results of Operations or "MD&A", as well as those described in the 2024 Annual Report on Form 10-K and this Quarterly Report on Form 10-Q under "Information Related to Forward-Looking Statements", Part I, Item 1A "Risk Factors" in the 2024 Annual Report on Form 10-K and Part II, Item 1A "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed with the SEC on May 9, 2025 and in this Quarterly Report on Form 10-Q. All dollar amounts in the below MD&A are presented in U.S. dollars, unless otherwise noted or the context otherwise provides.

Our MD&A is organized as follows:

● *Overview*. This section provides a general description of our business and operating segments as well as a brief discussion and overall analysis of our business and financial performance, including key developments affecting us during the three and nine months ended June 30, 2025 and 2024.

● *Critical Accounting Policies and Estimates.* This section discusses accounting policies and estimates that require us to exercise subjective or complex judgments in their application. We believe these accounting policies and estimates are important to understanding the assumptions and judgments incorporated in our reported financial results.

● *Results of Operations.* This section provides an analysis of our financial results for the three and nine months ended June 30, 2025 compared to the three and nine months ended June 30, 2024.

● *Liquidity and Capital Resources.* This section provides an analysis of our liquidity and changes in cash flows as well as a discussion of contractual commitments.

***Plan to Sell B Medical Systems Business***

During the first quarter of fiscal year 2025, we announced that we are pursuing a sale of our B Medical Systems business, a manufacturer and global distributor of medical refrigeration devices based in Luxembourg. This strategic action is intended to simplify our portfolio and allow management to focus on driving revenue growth and profitability in our core Sample Management Solutions and Multiomics segments. The B Medical Systems business has been classified as held for sale and a discontinued operation under generally accepted accounting principles in the United States, or GAAP. Unless otherwise noted, this MD&A relates solely to our continuing operations and excludes the operations of our B Medical Systems business.

**OVERVIEW**

We are a leading global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. We entered the life sciences market in 2011, leveraging our in-house precision automation and cryogenics capabilities that we were then applying in the semiconductor manufacturing market. This led us to develop solutions for automated ultra-cold storage. Since then, we have expanded our life sciences offerings through internal investments and through a series of acquisitions. We support our customers from research and clinical development to commercialization with our sample management and automated storage, as well as genomic services expertise to help our customers bring impactful therapies to market faster. We understand the importance of sample integrity and offer a broad portfolio of products and services supporting customers at every stage of the life cycle of samples including procurement, automated storage systems, genomic services and a multitude of sample consumables, informatics and data software, along with sample repository services. Our expertise, global footprint and leadership positions enable us to be a trusted global partner to pharmaceutical, biotechnology and life sciences research institutions. In total, we employ approximately 3,000 full-time employees, part-time employees and contingent workers worldwide as of June 30, 2025 and have sales in approximately 92 countries. We are headquartered in Burlington, Massachusetts and have operations in North America, Asia, and Europe.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 35

------

[**Table of Contents**](#toc)

Our portfolio includes product and service offerings developed by us internally, as well as acquired through acquisitions, designed to provide comprehensive capabilities to our customers, addressing their needs in sample exploration and management, automated storage and multiomics. We continue to develop new product and service offerings and enhance existing and acquired offerings through the expertise of our research and development resources. We believe our acquisition, investment and integration approach has allowed us to accelerate internal development and significantly accelerate time to market for our life sciences solutions.

**Segments** 

Within our Sample Management Solutions segment, we operate as a single business unit offering end-to-end sample management products and services, including: Sample Repository Services and Core Products (Automated Stores, Cryogenic Systems, Automated Sample Tube, Consumables and Instruments and Controlled Rate Thawing Devices). This portfolio provides customers with a high level of sample quality, security, availability, intelligence and integrity throughout the lifecycle of samples, providing customers with complete end-to-end "cold chain of custody" capabilities. We also offer expert-level consultation services to our clients throughout their experimental design and implementation processes.

Within our Multiomics segment, our genomic services business advances research and development activities by providing gene sequencing, synthesis, editing and related services. We offer a comprehensive, global portfolio that we believe has both broad appeal in the life sciences industry and enables customers to select the best solution for their research and development challenges. This portfolio also offers unique solutions for key markets such as cell and gene therapy, antibody development and biomarker discovery by addressing genomic complexity and throughput challenges.

**Business and Financial Performance**

***Basis of Presentation***

Our condensed consolidated financial statements are prepared in accordance with GAAP.

***Financial Performance***

Our performance for the three and nine months ended June 30, 2025 and 2024 is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** |
| *In thousands* | **2025** | **2024** | **2025** | **2024** |
| Revenue | $143942 | $144292 | $434870 | $422372 |
| Cost of revenue | 76182 | 78814 | 232553 | 234487 |
| Gross profit | 67760 | 65478 | 202317 | 187885 |
| Operating expenses |  |  |  |  |
| Research and development | 6685 | 6911 | 19934 | 21957 |
| Selling, general and administrative | 61035 | 63972 | 205836 | 202919 |
| &nbsp;&nbsp;&nbsp; Impairment of intangible assets |  |  |  | 4658 |
| Restructuring charges | 754 | 1701 | 4765 | 5915 |
| Total operating expenses | 68474 | 72584 | 230535 | 235449 |
| Operating loss | (714) | (7106) | (28218) | (47564) |
| Other income |  |  |  |  |
| Interest income, net | 4973 | 7925 | 13760 | 27359 |
| Other income (expense), net | (821) | (377) | 1539 | (127) |
| Income (loss) before income taxes | 3438 | 442 | (12919) | (20332) |
| Income tax expense | 2758 | 600 | 14007 | 3220 |
| Income (loss) from continuing operations | 680 | (158) | (26926) | (23552) |
| Loss from discontinued operations, net of tax | (53486) | (6424) | (79676) | (135634) |
| Net loss | $(52806) | $(6582) | $(106602) | $(159186) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 36

------

[**Table of Contents**](#toc)

Revenue was flat for the three months ended June 30, 2025 compared to the corresponding period in the prior fiscal year driven by revenue growth in Multiomics segment offset by lower revenue in Sample Management Solutions segment. Revenue increased 3% for the nine months ended June 30, 2025 compared to the corresponding period in the prior fiscal year driven by revenue growth in both our Sample Management Solutions and Multiomics segments. The revenue growth in our Sample Management Solutions segment for the nine months ended June 30, 2025 compared to the corresponding period in the prior fiscal year was primarily driven by strong performance in Sample Repository Solutions. The revenue growth in our Multiomics segment for the three and nine months ended June 30, 2025 compared to the corresponding periods in the prior fiscal year was primarily driven by Next Generation Sequencing services, partially offset by declines in Sanger sequencing and Gene Synthesis services. Gross margin was 47% for both the three and nine months ended June 30, 2025 compared to 45% and 44%, respectively, for the three and nine months ended June 30, 2024. The gross margin increase for the three months ended June 30, 2025 compared to the corresponding period in the prior fiscal year was mostly driven by operational efficiencies. The gross margin increase for the nine months ended June 30, 2025 compared to the corresponding period in the prior fiscal year was primarily driven by higher revenue, operational efficiencies, and favorable sales mix. Operating expenses for the three and nine months ended June 30, 2025 decreased $4.1 million and $4.9 million, respectively, compared to the corresponding periods in the prior fiscal year, primarily driven by lower research and development expense, partially offset by higher transformation costs. The non-recurring impairment of intangible assets recorded in the three months ended March 31, 2024 also contributed to the decrease in the nine months ended June 30, 2025 compared to the corresponding period in the prior fiscal year. We generated a net income from continuing operations of $0.7 million and a net loss from continuing operations of $26.9 million, respectively, for the three and nine months ended June 30, 2025 compared to net loss from continuing operations of $0.2 million and $23.6 million, respectively, for the corresponding periods in the prior fiscal year, primarily driven by higher profit margin and operational efficiencies, partially offset by lower interest income and higher income tax expense. We generated net loss from discontinued operations, net of tax, of $51.9 million and $78.1 million, respectively, for the three and nine months ended June 30, 2025 compared to net loss from discontinued operations, net of tax, of $6.4 million and $135.6 million, respectively, for the corresponding periods in the prior fiscal year, primarily driven by the loss on assets held for sale recorded in the three and nine months ended June 30, 2025 and the impairment of goodwill recorded in the nine months ended June 30, 2024.

**CRITICAL ACCOUNTING POLICIES AND ESTIMATES**

The preparation of the interim condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates based on historical experience and consider various other assumptions that are believed to be reasonable under the circumstances. We evaluate current and anticipated worldwide economic conditions, both in general and specifically in relation to the life sciences industry, that serve as a basis for making judgments about the carrying values of assets and liabilities that are not readily determinable based on information from other sources. Actual results may differ from these estimates under different assumptions or conditions that could have a material impact on our financial condition and results of operations.

The critical accounting estimates that we believe affect our more significant judgments and estimates used in the preparation of our condensed consolidated financial statements presented in this Quarterly Report on Form 10-Q are described under Critical Accounting Policies Estimates included in the section titled "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Part II, Item 7 of the 2024 Annual Report on Form 10-K. There have been no material changes to our critical accounting policies or estimates from those set forth in our Annual Report on Form 10-K.

**RESULTS OF OPERATIONS**

Please refer to the commentary provided below for further discussion and analysis of the factors contributing to our results of operations for the three and nine months ended June 30, 2025 compared to the three and nine months ended June 30, 2024.

**Non-GAAP Financial Measures**

Non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and should not be relied upon to the exclusion of GAAP financial measures. Management adjusts the GAAP results for the impact of amortization and impairment of intangible assets, transformation costs, restructuring charges, governance-related matters, merger and acquisition costs and costs related to share repurchase, and other unallocated corporate expenses to provide investors better perspective on the results of operations which we believe is more comparable to the similar analysis provided by our peers. Management also excludes special charges and gains, such as gains and losses from the sale of assets, certain tax benefits and charges, as well as other gains and charges that are not representative of the normal operations of the business. Management strongly encourages investors to review our financial statements and publicly filed reports in their entirety and not rely on any single measure. A reconciliation of non-GAAP measures to the most nearly comparable GAAP measures is included under "Operating Income (Loss)" and "Gross Margin" below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 37

------

[**Table of Contents**](#toc)

**Revenue** 

Our revenue performance for the three and nine months ended June 30, 2025 and 2024 is as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** |
|  |  |  | **% Change** |  |  | **% Change** |
| *In thousands, except percentages* | **2025** | **2024** | **2025 v. 2024** | **2025** | **2024** | **2025 v. 2024** |
| Sample Management Solutions | $77707 | $80673 | *(3.7)%* | $238816 | $233816 | *2.1 %* |
| Multiomics | 66235 | 63619 | *4.1 %* | 196054 | 188556 | *4.0 %* |
| Total revenue | $143942 | $144292 | (0.2)% | $434870 | $422372 | 3.0% |

---

Our Sample Management Solutions segment revenue for the three months ended June 30, 2025 decreased 4% compared to the corresponding prior fiscal year period driven by lower revenue in Core Products, particularly in Automated Stores and Cryogenic Systems, partially offset by higher revenue in Sample Storage. Our Sample Management Solutions segment revenue for the nine months ended June 30, 2025 increased 2% compared to the corresponding prior fiscal year period driven by revenue growth in Sample Repository Services.

Our Multiomics segment revenue for the three and nine months ended June 30, 2025 increased approximately 4% in each period compared to the corresponding prior fiscal year periods driven by revenue growth in Next Generation Sequencing services, partially offset by declines in Gene Synthesis and Sanger sequencing services.

Revenue generated outside the United States was 39.0% and 37.6% of total revenue, respectively, for the three and nine months ended June 30, 2025 compared to 34.1% and 35.4% of total revenue, respectively, for the corresponding prior fiscal year periods.

**Operating Income (Loss)**

Our operating income (loss) performance for the three and nine months ended June 30, 2025 and 2024 is as follows (in thousands, except percentages):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** |
|  | **Sample Management Solutions** | **Sample Management Solutions** | **Multiomics** | **Multiomics** |
|  | **2025** | **2024** | **2025** | **2024** |
| **Revenue:** | $77707 | $80673 | $66235 | $63619 |
| **Operating income (loss):** |  |  |  |  |
| Operating income (loss) | $9834 | $2647 | $(4191) | $(1630) |
| Amortization of completed technology | 1208 | 1010 | 860 | 1038 |
| Transformation costs<sup>(1)</sup> | 168 | (127) |  |  |
| Other adjustments | 38 | 52 |  |  |
| Total adjusted operating income (loss) | $11248 | $3582 | $(3331) | $(592) |
| *Operating margin* | *12.7 %* | *3.3 %* | *(6.3)%* | *(2.6)%* |
| *Adjusted operating margin* | *14.5 %* | *4.4 %* | *(5.0)%* | *(0.9)%* |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 38

------

[**Table of Contents**](#toc)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** |
|  | **Segment** | **Segment** | **Corporate** | **Corporate** | **Azenta Total** | **Azenta Total** |
|  | **2025** | **2024** | **2025** | **2024** | **2025** | **2024** |
| **Revenue:** | $143942 | $144292 | $— | $— | $143942 | $144292 |
| **Operating income (loss):** |  |  |  |  |  |  |
| Operating income (loss) | $5643 | $1017 | $(6357) | $(8123) | $(714) | $(7106) |
| Amortization of completed technology | 2068 | 2048 |  | (1) | 2068 | 2047 |
| Amortization of other intangible assets |  |  | 4123 | 5132 | 4123 | 5132 |
| Transformation costs<sup>(1)</sup> | 168 | (127) | 1374 | 1301 | 1542 | 1174 |
| Restructuring charges |  |  | 754 | 1701 | 754 | 1701 |
| Merger and acquisition costs and costs related to share repurchase<sup>(2)</sup> |  |  | 58 | 74 | 58 | 74 |
| Other adjustments | 38 | 52 | 2 | (53) | 40 | (1) |
| &nbsp;&nbsp;&nbsp; Total adjusted operating income (loss) | $7917 | $2990 | $(46) | $31 | $7871 | $3021 |
| &nbsp;&nbsp;&nbsp; *Operating margin* | 3.9% | 0.7% |  |  | (0.5)% | (4.9)% |
| &nbsp;&nbsp;&nbsp; *Adjusted operating margin* | 5.5% | 2.1% |  |  | 5.5% | 2.1% |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** |
|  | **Sample Management Solutions** | **Sample Management Solutions** | **Multiomics** | **Multiomics** |
|  | **2025** | **2024** | **2025** | **2024** |
| **Revenue:** | $238816 | $233816 | $196054 | $188556 |
| **Operating income (loss):** |  |  |  |  |
| Operating income (loss) | $11963 | $(1733) | $(13710) | $(9853) |
| Amortization of completed technology | 3296 | 2852 | 2580 | 3118 |
| Amortization of other intangible assets |  | 103 |  |  |
| Transformation costs<sup>(1)</sup> | 2877 | 232 |  |  |
| Other adjustments | 41 | 55 | 3 | (1) |
| Total adjusted operating income (loss) | $18177 | $1509 | $(11127) | $(6736) |
| *Operating margin* | *5.0 %* | *(0.7)%* | *(7.0)%* | *(5.2)%* |
| *Adjusted operating margin* | *7.6 %* | *0.6 %* | *(5.7)%* | *(3.6)%* |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 39

------

[**Table of Contents**](#toc)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** |
|  | **Segment** | **Segment** | **Corporate** | **Corporate** | **Azenta Total** | **Azenta Total** |
|  | **2025** | **2024** | **2025** | **2024** | **2025** | **2024** |
| **Revenue:** | $434870 | $422372 | $— | $— | $434870 | $422372 |
| **Operating loss:** |  |  |  |  |  |  |
| Operating loss | $(1747) | $(11586) | $(26471) | $(35978) | $(28218) | $(47564) |
| Amortization of completed technology | 5876 | 5970 |  |  | 5876 | 5970 |
| Amortization of other intangible assets |  | 103 | 12499 | 15552 | 12499 | 15655 |
| Transformation costs<sup>(1)</sup> | 2877 | 232 | 6894 | 5078 | 9771 | 5310 |
| Restructuring charges |  |  | 4765 | 5915 | 4765 | 5915 |
| Impairment of intangible assets |  |  |  | 4658 |  | 4658 |
| Merger and acquisition costs and costs related to share repurchase<sup>(2)</sup> |  |  | 2316 | 4821 | 2316 | 4821 |
| Other adjustments | 44 | 54 | (3) | (56) | 41 | (2) |
| Total adjusted operating income (loss) | $7050 | $(5227) | $— | $(10) | $7050 | $(5237) |
| *Operating margin* | *(0.4)%* | *(2.7)%* |  |  | *(6.5)%* | *(11.3)%* |
| *Adjusted operating margin* | *1.6 %* | *(1.2)%* |  |  | *1.6 %* | *(1.2)%* |

---

(1) Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design.

(2) Includes expenses related to governance-related matters.

Operating income for the Sample Management Solutions segment was $9.8 million and $12.0 million, respectively, for the three and nine months ended June 30, 2025 compared to operating income of $2.6 million and operating loss of $1.7 million, respectively, for the corresponding periods in the prior fiscal year. The Sample Management Solutions segment operating margin increased 937 basis points and 575 basis points, respectively, for the three and nine months ended June 30, 2025 compared to the corresponding periods in the prior fiscal year. The increases in operating income and operating margin were primarily driven by gross margin expansion, partially offset by increased transformation costs. Adjusted operating income was $11.2 million and $18.2 million, respectively, for the three and nine months ended June 30, 2025 compared to adjusted operating income of $3.6 million and $1.5 million, respectively, for the corresponding periods in the prior fiscal year. Adjusted operating margin increased 1,003 basis points and 697 basis points, respectively, for the three and nine months ended June 30, 2025 compared to the corresponding periods in the prior fiscal year. Adjusted operating income and margin exclude the impact of amortization of intangible assets, transformation costs and other adjustments.

Operating loss for the Multiomics segment was $4.2 million and $13.7 million, respectively, for the three and nine months ended June 30, 2025 compared to an operating loss of $1.6 million and $9.9 million, respectively, for the corresponding periods in the prior fiscal year. The Multiomics segment operating margin decreased 377 basis points and 177 basis points, respectively, for the three and nine months ended June 30, 2025 compared to the corresponding periods in the prior fiscal year. The increase in operating loss and decrease in operating margin were primarily driven by lower revenue for Gene Synthesis and Sanger sequencing services, partially offset by higher revenue for Next Generation Sequencing services. Adjusted operating loss was $3.3 million and $11.1 million, respectively, for the three and nine months ended June 30, 2025 compared to adjusted operating loss of $0.6 million and $6.7 million, respectively, for the corresponding periods in the prior fiscal year. Adjusted operating margin decreased 410 basis points and 210 basis points, respectively, for the three and nine months ended June 30, 2025 compared to the corresponding periods in the prior fiscal year. Adjusted operating loss and margin exclude the impact of amortization related to completed technology, restructuring charges and other adjustments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 40

------

[**Table of Contents**](#toc)

**Gross Margin**

Our gross margin performance for the three and nine months ended June 30, 2025 and 2024 is as follows (in thousands, except percentages):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** |
|  | **Sample Management Solutions** | **Sample Management Solutions** | **Multiomics** | **Multiomics** | **Azenta Total** | **Azenta Total** |
|  | **2025** | **2024** | **2025** | **2024** | **2025** | **2024** |
| Revenue | $77707 | $80673 | $66235 | $63619 | $143942 | $144292 |
| Gross profit | $40437 | $36279 | $27323 | $29199 | $67760 | $65478 |
| <u>Adjustments:</u> |  |  |  |  |  |  |
| Amortization of completed technology | 1208 | 1010 | 860 | 1038 | 2068 | 2048 |
| Transformation costs<sup>(1)</sup> |  | (127) |  |  |  | (127) |
| &nbsp;&nbsp;&nbsp; Other adjustments | 25 |  |  |  | 25 |  |
| Adjusted gross profit | $41670 | $37162 | $28183 | $30237 | $69853 | $67399 |
| *Gross margin* | *52.0 %* | *45.0 %* | *41.3 %* | *45.9 %* | *47.1 %* | *45.4 %* |
| *Adjusted gross margin* | *53.6 %* | *46.1 %* | *42.6 %* | *47.5 %* | *48.5 %* | *46.7 %* |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** |
|  | **Sample Management Solutions** | **Sample Management Solutions** | **Multiomics** | **Multiomics** | **Azenta Total** | **Azenta Total** |
|  | **2025** | **2024** | **2025** | **2024** | **2025** | **2024** |
| Revenue | $238816 | $233816 | $196054 | $188556 | $434870 | $422372 |
| Gross profit | $116802 | $102494 | $85515 | $85391 | $202317 | $187885 |
| <u>Adjustments:</u> |  |  |  |  |  |  |
| Amortization of completed technology | 3296 | 2852 | 2580 | 3118 | 5876 | 5970 |
| Transformation costs<sup>(1)</sup> | 52 | 232 |  |  | 52 | 232 |
| Other adjustments | 25 |  |  |  | 25 |  |
| Adjusted gross profit | $120175 | $105578 | $88095 | $88509 | $208270 | $194087 |
| *Gross margin* | *48.9 %* | *43.8 %* | *43.6 %* | *45.3 %* | *46.5 %* | *44.5 %* |
| *Adjusted gross margin* | *50.3 %* | *45.2 %* | *44.9 %* | *46.9 %* | *47.9 %* | *46.0 %* |

---

(1) Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 41

------

[**Table of Contents**](#toc)

The Sample Management Solutions segment gross margin increased 707 basis points and 507 basis points, respectively, for the three and nine months ended June 30, 2025 compared to the corresponding periods in the prior fiscal year. Adjusted gross margin increased 756 basis points and 517 basis points, respectively, for the three and nine months ended June 30, 2025, compared to the corresponding periods in the prior fiscal year. The increases in gross margin and adjusted gross margin were primarily driven by operational efficiencies and favorable sales mix.

The Multiomics segment gross margin decreased 465 basis points and 167 basis points, respectively, for the three and nine months ended June 30, 2025 compared to the corresponding periods in the prior fiscal year. Adjusted gross margin decreased 498 basis points and 201 basis points, respectively, for the three and nine months ended June 30, 2025 compared to the corresponding periods in the prior fiscal year. The decreases in gross margin and adjusted gross margin were primarily driven by lower revenue for Gene Synthesis and Sanger sequencing services, partially offset by higher revenue for Next Generation Sequencing services.

**Research and Development Expenses**

Our research and development expenses for the three and nine months ended June 30, 2025 and 2024 are as follows:

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** |
|  | **2025** | **2025** | **2025** | **2024** | **2024** | **2024** | **2025** | **2025** | **2025** | **2024** | **2024** | **2024** |
|  | *In thousands* | *% of Revenue* | *% of Revenue* | *In thousands* | *% of Revenue* | *% of Revenue* | *In thousands* | *% of Revenue* | *% of Revenue* | *In thousands* | *% of Revenue* | *% of Revenue* |
| Sample Management Solutions | $4018 | | *5.2 %* | $4174 | | *5.2 %* | $11903 | | *5.0 %* | $13170 | | *5.6 %* |
| Multiomics | 2667 | | *4.0 %* | 2737 | | *4.3 %* | 8031 | | *4.1 %* | 8787 | | *4.7 %* |
| Total research and development expense | $6685 | | *4.6 %* | $6911 | | *4.8 %* | $19934 | | *4.6 %* | $21957 | | *5.2 %* |

---

Total research and development expenses decreased $0.2 million and $2.0 million, respectively, for the three and nine months ended June 30, 2025 compared to the corresponding periods in the prior fiscal year, driven by cost reduction initiatives across the business, primarily decreased compensation and benefits expense.

**Selling, General and Administrative Expenses**

Our selling, general and administrative expenses for the three and nine months ended June 30, 2025 and 2024 are as follows:

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** |
|  | **2025** | **2025** | **2025** | **2024** | **2024** | **2024** | **2025** | **2025** | **2025** | **2024** | **2024** | **2024** |
|  | *In thousands* | *% of Revenue* | *% of Revenue* | *In thousands* | *% of Revenue* | *% of Revenue* | *In thousands* | *% of Revenue* | *% of Revenue* | *In thousands* | *% of Revenue* | *% of Revenue* |
| Sample Management Solutions | $26584 | | *34.2 %* | $29418 | | *36.5 %* | $92935 | | *38.9 %* | $91017 | | *38.9 %* |
| Multiomics | 28848 | | *43.6 %* | 28092 | | *44.2 %* | 91196 | | *46.5 %* | 86454 | | *45.9 %* |
| Corporate | 5603 | | *3.9 %* | 6462 | | *4.5 %* | 21705 | | *5.0 %* | 25448 | | *6.0 %* |
| Total selling, general and administrative expense | $61035 | | *42.4 %* | $63972 | | *44.3 %* | $205836 | | *47.3 %* | $202919 | | *48.0 %* |

---

Total selling, general and administrative expenses decreased $2.9 million for the three months ended June 30, 2025 compared to the corresponding period in the prior fiscal year, primarily due to decreased compensation and benefits expense. Total selling, general and administrative expenses increased $2.9 million for the nine months ended June 30, 2025 compared to the corresponding period in the prior fiscal year, primarily due to higher stock-based compensation expense and one-time costs related to the Company's leadership changes, partially offset by decreased compensation and benefits expense.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 42

------

[**Table of Contents**](#toc)

**Restructuring Charges**

Restructuring charges were $0.8 million for the three months ended June 30, 2025, a decrease of $0.9 million compared to the corresponding period in the prior fiscal year. Restructuring charges were $4.8 million for the nine months ended June 30, 2025, a decrease of $1.2 million compared to the corresponding period in the prior fiscal year. Please refer to Note 7, *Restructuring* in the notes to the unaudited condensed consolidated financial statements included in the section titled "Financial Statements" in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information.

**Non-Operating Income** 

*Interest income, net* – We recorded interest income of $5.0 million and $13.8 million for the three and nine months ended June 30, 2025, respectively, compared to $7.9 million and $27.4 million recorded for the three and nine months ended June 30, 2024, respectively. The decrease in interest income year over year is due to decreased investments in marketable securities. Please refer to Note 4, *Marketable Securities* and Note 5, *Derivative Instruments* in the notes to the unaudited condensed consolidated financial statements included in the section titled "Financial Statements" in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information.

*Other income (expense), net* – We recorded other expense of $0.8 million for the three months ended June 30, 2025 compared to $0.4 million in the corresponding period in the prior fiscal year. We recorded other income of $1.5 million for the nine months ended June 30, 2025, an increase of $1.7 million compared to the corresponding period in the prior fiscal year. Other income (expense) primarily relates to foreign exchange gains and losses resulting from foreign currency denominated transactions and the revaluation of foreign currency denominated assets and liabilities. The increase in the nine months ended June 30, 2025 was also attributable to a $2.1 million gain from cash proceeds received from a cost method investment which had no cost basis.

**Income Tax Expense** 

We recorded income tax expense of $2.8 million and $14.0 million during the three and nine months ended June 30, 2025, respectively. The tax expense for the three and nine months ended June 30, 2025 was primarily driven by a $6.5 million tax expense related to a change in the indefinite reinvestment assertion and the expectation to repatriate cash to the United States from a China subsidiary. The tax expense is also driven by profits in foreign jurisdictions and current state income taxes in jurisdictions where we do not have a net operating loss carryover. Additionally, tax expense is generated on a global loss because we do not benefit from the U.S. tax loss due to a valuation allowance against U.S. deferred tax assets.

We recorded income tax expense of $0.6 million and $3.2 million during the three and nine months ended June 30, 2024, respectively. The tax expense was primarily driven by a $1.7 million charge related to a valuation allowance recorded against deferred tax assets in a foreign subsidiary during the three months ended March 31, 2024. Tax expense also includes $0.5 million of stock compensation shortfall expense for tax deductions that were lower than the associated book compensation expense during the three and nine months ended June 30, 2024 and $0.7 million of expenses related to a valuation allowance on beginning of year U.S. state deferred tax assets.

On July 4, 2025, the "One Big Beautiful Bill Act" was signed into US tax law, extending many international tax provisions of the 2017 Tax Cuts and Jobs Act and providing additional favorable incentives. We will continually monitor the financial impact of these changes. In the near term, we do not expect these changes to have a significant effect on our effective tax rate or cash flows.

**Discontinued Operations**

During the first quarter of fiscal year 2025, following approval by our Board of Directors, we publicly announced our plan to sell the B Medical Systems business. Results related to the B Medical Systems business are included within discontinued operations for the three and nine months ended June 30, 2025 and 2024. Revenue from discontinued operations was $16.3 million and $28.5 million for the three months ended June 30, 2025 and 2024, respectively. Revenue from discontinued operations was $51.1 million and $63.9 million for the nine months ended June 30, 2025 and 2024, respectively. Loss from discontinued operations, net of tax, was $53.5 million and $79.7 million for the three and nine months ended June 30, 2025, respectively, primarily driven by the loss on assets held for sale recorded in the three and nine months ended June 30, 2025. Loss from discontinued operations was $6.4 million and $135.6 million for the three and nine months ended June 30, 2024, respectively, primarily driven by the impairment of goodwill recorded in the nine months ended June 30, 2024. Loss from discontinued operations includes only direct operating expenses incurred that (1) are clearly identifiable as costs being disposed of upon completion of the sale and (2) will not be continued by the Company on an ongoing basis. Indirect expenses which supported the B Medical Systems business and remain part of continuing operations, are not reflected in loss from discontinued operations. Please refer to Note 3, *Discontinued Operations*, in the notes to the unaudited condensed consolidated financial statements included in the section titled "Financial Statements" in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 43

------

[**Table of Contents**](#toc)

**LIQUIDITY AND CAPITAL RESOURCES**

As of June 30, 2025, we had cash and cash equivalents, restricted cash, and marketable securities of $549.8 million and stockholders' equity of $1.7 billion. We believe that our current cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements for at least one year from the date of this Quarterly Report on Form 10-Q and for the foreseeable future thereafter. The current global economic environment makes it difficult for us to predict longer-term liquidity requirements with sufficient certainty. We may be unable to obtain financing that may be required on terms favorable to us, if at all. If adequate funds are not available to us on acceptable terms or otherwise, we may be unable to successfully develop or enhance products and services, respond to competitive pressures, or take advantage of acquisition opportunities, any of which could have a material adverse effect on our business, financial condition and operating results.

**Cash Flows and Liquidity**

Our cash and cash equivalents, restricted cash and marketable securities for our continuing operations as of June 30, 2025 and September 30, 2024 are as follows:

---

| | | |
|:---|:---|:---|
| *In thousands* | **June 30, 2025** | **September 30, 2024** |
| Cash and cash equivalents | $270040 | $280030 |
| Restricted cash | 8776 | 10061 |
| Short-term marketable securities | 48817 | 151162 |
| Long-term marketable securities | 222168 | 49454 |
|  | $549801 | $490707 |

---

As of June 30, 2025, we had $121.9 million of cash, cash equivalents and restricted cash held outside of the United States which are not currently needed for U.S. operations. We had approximately $23 million of cash in China as of June 30, 2025. We began repatriating the cash to the United States from China during the third quarter of the fiscal year 2025 and have provided for $6.5 million of income taxes related to the repatriation plan as of June 30, 2025. Our marketable securities are generally readily convertible to cash without a material adverse impact.

Our cash flows on a total company consolidated basis for the nine months ended June 30, 2025 and 2024 were as follows:

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended June 30,** | **Nine Months Ended June 30,** |
| *In thousands* | **2025** | **2024** |
| Net cash provided by operating activities | $70011 | $32151 |
| Net cash (used in) provided by investing activities | (91287) | 26732 |
| Net cash used in financing activities | (10408) | (411661) |
| Effects of exchange rate changes on cash, cash equivalents and restricted cash | 4510 | 15596 |
| &nbsp;&nbsp;&nbsp; Net decrease in cash, cash equivalents and restricted cash | $(27174) | $(337182) |

---

Cash inflows from operating activities for the nine months ended June 30, 2025 were $70.0 million, primarily due to increased revenue and collections and a U.S. federal tax refund of $11.5 million received in the nine months ended June 30, 2025. Investing activities for the nine months ended June 30, 2025 include $313.0 million in purchases of marketable securities, partially offset by $242.5 million in sales and maturities of marketable securities. Financing activities for the nine months ended June 30, 2025 include $11.4 million of excise tax payments related to our share repurchases settled in fiscal year 2024.

As of June 30, 2025, we had no outstanding debt on our balance sheet.

**Capital Resources**

***Contractual Obligations and Requirements***

As of June 30, 2025, we had non-cancellable commitments of $48.7 million comprised of purchase orders for inventory of $37.3 million and other operating expense commitments of $11.4 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 44

------

[**Table of Contents**](#toc)

**Item 3. *Quantitative and Qualitative Disclosures About Market Risk***

We are exposed to a variety of market risks, including changes in interest rates affecting the return on our cash and cash equivalents, restricted cash and short-term and long-term investments and fluctuations in foreign currency exchange rates.

**Interest Rate Exposure**

Our cash and cash equivalents and restricted cash consist principally of money market securities which are short-term in nature. At June 30, 2025, our aggregate short-term and long-term investments were $271.0 million, consisting mostly of highly rated corporate debt securities and U.S. government backed securities. At June 30, 2025, there was a net unrealized loss position of $0.1 million on marketable securities included in "Accumulated other comprehensive loss" in the Condensed Consolidated Balance Sheets. A hypothetical 100 basis point change in interest rates would result in a $2.7 million and $6.1 million change in interest income earned during the nine months ended June 30, 2025 and 2024, respectively.

**Currency Rate Exposure**

We have transactions and balances denominated in currencies other than the functional currency of the transacting entity. Most of these transactions carrying foreign exchange risk are in Germany, the United Kingdom, and China. Sales in currencies other than the U.S. dollar were approximately 34% and 29% of our total sales, respectively, during the nine months ended June 30, 2025 and 2024. These sales were made primarily by our foreign subsidiaries, which have cost structures that substantially align with the currency of sale.

In the normal course of our business, we have liquid assets denominated in non-functional currencies which include cash, short-term advances between our legal entities and accounts receivable which are subject to foreign currency exposure. Such balances were $50.7 million and $63.9 million, respectively, at June 30, 2025 and September 30, 2024, and primarily relate to the Euro and British Pound. We mitigate the impact of potential currency translation losses on these short-term intercompany advances by the timely settlement of each transaction, generally within 30 days. We also utilize forward contracts to mitigate our exposures to currency movement. We incurred foreign currency losses of $1.3 million and $1.5 million during the nine months ended June 30, 2025 and 2024, respectively, which related to the currency fluctuation on these balances between the time the transaction occurred and the ultimate settlement of the transaction. A hypothetical 10% change in foreign exchange rates as of June 30, 2025 would result in an approximate change of $0.4 million in our net loss during the nine months ended June 30, 2025.

**Item 4. *Controls and Procedures***

*Evaluation of Disclosure Controls and Procedures*. Under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Exchange Act. Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to management, including the chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon this evaluation, our chief executive officer and our chief financial officer concluded that our disclosure controls and procedures were not effective as of June 30, 2025 due to the material weaknesses described below. Notwithstanding the material weaknesses, our chief executive officer and our chief financial officer have concluded that the unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q are fairly stated in all material respects in accordance with GAAP for each of the periods presented.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 45

------

[**Table of Contents**](#toc)

*Material Weaknesses in Internal Control over Financial Reporting.* As previously disclosed in the 2024 Annual Report on Form 10-K, we identified a material weakness in our internal control over financial reporting as we did not design and maintain effective controls related to the review of the cash flow statement. This material weakness, which continues to exist as of June 30, 2025, resulted in immaterial misstatements in our Consolidated Statements of Cash Flows for the Q2 and Q3 interim periods during fiscal year 2023, the year ended September 30, 2023, the Q1, Q2, and Q3 interim periods during fiscal year 2024, the Q1 interim period during fiscal year 2025, and in our supplemental cash flow disclosures for the year ended September 30, 2022, each interim and annual period during fiscal year 2023 and the Q1, Q2 and Q3 interim periods during fiscal year 2024.

During the second quarter of fiscal year 2025, we identified an additional material weakness in our internal control over financial reporting, as we did not design and maintain effective controls related to the preparation and review of account reconciliations. This material weakness, which continues to exist as of June 30, 2025, resulted in immaterial misstatements in our Consolidated Financial Statements for the Q1 and Q2 interim periods during fiscal year 2025.

Additionally, the material weaknesses could result in misstatements of substantially all account balances and disclosures that would result in a material misstatement to our interim or annual consolidated financial statements that would not be prevented or detected on a timely basis.

*Remediation Plans*

*Statements of Cash Flows -* During the three months ended December 31, 2024, we took steps to remediate the material weakness described above, including implementing a new cash flow reporting tool which automates the calculation of the effect of exchange rate changes on cash and cash equivalents, and we implemented and documented new processes and controls over the review of our consolidated statement of cash flows. We continued to monitor and evaluate the effectiveness of these changes to our controls during the quarter ended June 30, 2025. While the new and enhanced controls have been designed and implemented, they have not operated for a sufficient period as of June 30, 2025 to assert the material weakness has been remediated.

*Account Reconciliations* – Our management is in the process of implementing a plan to remediate the material weakness related to the preparation and review of account reconciliations described above. We intend to take the necessary steps to address this material weakness by designing and implementing controls to resolve the underlying cause of this material weakness. Our planned remediation actions currently include, but are not limited to, the following:

● design and implementation of enhanced controls, operating at the level necessary to prevent and detect potential material misstatements and to aid in the detection of potential deviations in balance sheet accounts;

● redesign and implementation of the balance sheet account reconciliation policy and approval process, incorporating enhanced training and establishing additional controls or control activities, with appropriate levels of evidence regarding aging, thresholds and supporting documentation; and

● engagement with outside consultants to assist in certain aspects of the remediation plan.

These material weaknesses will not be considered remediated until the applicable controls operate for a sufficient period for management to conclude, through testing, that such controls are operating effectively. We are committed to continuing to improve our internal control over financial reporting, and as we continue to evaluate and work to improve our internal control over financial reporting, we may take additional measures to address control deficiencies, or we may modify certain remediation measures.

*Changes in Internal Control over Financial Reporting*. Other than the remediation plans described above, there were no changes in our internal control over financial reporting that occurred during the quarter ended June 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 46

------

[**Table of Contents**](#toc)

**PART II. OTHER INFORMATION**

**Item 1. *Legal Proceedings***

We are subject to various legal proceedings, both asserted and unasserted, that arise in the ordinary course of business. We cannot predict the ultimate outcome of such legal proceedings or in certain instances provide reasonable ranges of potential losses. However, as of the date of this Quarterly Report on Form 10-Q, we believe that none of these claims will have a material adverse effect on our consolidated financial condition or results of operations, in each case, for continuing operations. Please refer to Note 3, *Discontinued Operations* and Note 16, *Commitments and Contingencies* in the notes to the unaudited condensed consolidated financial statements included in the section titled "Financial Statements" in Part I, Item 1 of this Quarterly Report on Form 10-Q, for additional information about our legal proceedings. In the event of unexpected subsequent developments and given the inherent unpredictability of these legal proceedings, there can be no assurance that our assessment of any claim will reflect the ultimate outcome and an adverse outcome in certain matters could, from time to time, have a material adverse effect on our consolidated financial condition or results of operations in particular quarterly or annual periods.

**Item 1A. *Risk Factors***

You should carefully review and consider the information regarding certain factors that could materially affect our business, consolidated financial condition or results of operations set forth under the section titled "Risk Factors" in Part I, Item 1A of the 2024 Annual Report on Form 10-K and in Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed with the SEC on May 9, 2025. There have been no material changes from the risk factors disclosed in the 2024 Annual Report on Form 10-K and such Quarterly Report on Form 10-Q. We may disclose additional changes to risk factors or additional factors from time to time in our future filings with the SEC.

**Item *5. Other Information***

**Rule *10b5*-*1* Trading Arrangements** 

During the *three* months ended *June 30, 2025*, no director nor officer of the Company adopted, modified or terminated a Rule *10b5*-*1* trading arrangement or non-Rule *10b5*-*1* trading arrangement, as each term is defined in Item *408* of Regulation S-K.

**Appointment of Principal Accounting Officer**

In connection with the previously announced voluntary resignation of Violetta Hughes, Vice President and Chief Accounting Officer (Principal Accounting Officer), on *June 27, 2025,* the Company appointed Lawrence Lin, the Company's Executive Vice President and Chief Financial Officer, to act as the Company's Principal Accounting Officer, effective as of *August 7, 2025.* Mr. Lin will *not* receive any additional consideration in connection with this appointment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *47*

------

[**Table of Contents**](#toc)

**Item 6. *Exhibits***

The following exhibits are included herein:

---

| | |
|:---|:---|
| **Exhibit**<br> **No.** | **Description** |
| 10.1\* | [Severance Agreement and Release, dated April 9, 2025, between the Company and David Wang (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, File No. 000-25434, filed on April 9, 2025).](http://www.sec.gov/Archives/edgar/data/933974/000143774925011527/ex_800013.htm) |
| 10.2\* | [Severance Agreement and Release, dated May 15, 2025, between the Company and Jason W. Joseph (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, File No. 000-25434, filed on May 16, 2025).](http://www.sec.gov/Archives/edgar/data/933974/000143774925017419/ex_819534.htm) |
| 31.01 | [<u>Certification of the Company's Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>](ex_818313.htm) |
| 31.02 | [<u>Certification of the Company's Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>](ex_818314.htm) |
| 32 | [<u>Certification of the Company's Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>](ex_818315.htm) |
| 101 | The following material from the Company's Quarterly Report on Form 10-Q, for the quarter ended June 30, 2025, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the unaudited Condensed Consolidated Balance Sheets; (ii) the unaudited Condensed Consolidated Statements of Operations; (iii) the unaudited Condensed Consolidated Statements of Comprehensive Income (Loss); (iv) the unaudited Condensed Consolidated Statements of Cash Flows; (v) the unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity; and (vi) the Notes to the unaudited Condensed Consolidated Financial Statements. The instance document does not appear in the Interactive Data File because XBRL tags are embedded in the iXBRL document. |
| 104 | Cover Page Interactive Data File (formatted as iXBRL and contained in Exhibit 101). |

---

\* Management contract, compensatory plan or agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 48

------

[**Table of Contents**](#toc)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | AZENTA, INC. |
| Date: August 6, 2025 | /s/ Lawrence Lin |
|  | Lawrence Lin |
|  | *Executive Vice President and Chief Financial Officer* |
|  | *(Principal Financial Officer)* |
| Date: August 6, 2025 | /s/ Violetta A. Hughes |
|  | Violetta A. Hughes |
|  | *Vice President and Chief Accounting Officer* |
|  | *(Principal Accounting Officer)* |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 49

## Exhibit 31.01

**Exhibit 31.01**

**CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, John Marotta, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| |
|:---|
| <br> /s/ John Marotta |
| John Marotta |
| President and Chief Executive Officer<br> (Principal Executive Officer) |
| Date: August 6, 2025 |

---

## Exhibit 31.02

**Exhibit 31.02**

**CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Lawrence Lin, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| |
|:---|
| <br> /s/ Lawrence Lin |
| Lawrence Lin |
| Executive Vice President and Chief Financial Officer<br> (Principal Financial Officer) |
| Date: August 6, 2025 |

---

## Ex-32

**Exhibit 32**

**CERTIFICATION**

**Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)**

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of Azenta, Inc., a Delaware corporation (the "Company"), does hereby certify, to the best of such officer's knowledge and belief, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (this "Form 10-Q") of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in this Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| Dated: August 6, 2025 | <br> /s/ John Marotta |
|  | John Marotta |
|  | President and Chief Executive Officer |
|  | (Principal Executive Officer) |
| Dated: August 6, 2025 | <br> /s/ Lawrence Lin |
|  | Lawrence Lin |
|  | Executive Vice President and |
|  | Chief Financial Officer |
|  | (Principal Financial Officer) |

---

A signed original of this written statement required by Section 906 has been provided to Azenta, Inc. and will be retained by Azenta, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.